Ask OpenScientist

Ask a research question about Kawasaki Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
2
Pathophys.
40
Phenotypes
2
Pathograph
21
Genes
6
Treatments
7
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
CARDIOVASCULAR IMMUNE_RHEUMATOLOGIC
👪

Inheritance

1
Polygenic inheritance HP:0010982
Kawasaki disease has a multigenic/multifactorial inheritance pattern with susceptibility loci identified in ITPKC, FCGR2A, BLK, CD40, CASP3, and HLA regions.
Polygenic inheritance
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"Multigenic/multifactorial"
Orphanet classifies the inheritance pattern of Kawasaki disease as multigenic/multifactorial.

Pathophysiology

2
Vascular Inflammation
Widespread inflammation of medium-sized arteries, including coronary arteries.
vascular endothelial cell link neutrophil link monocyte link macrophage link
endothelial cell activation link leukocyte adhesion to vascular endothelial cell link inflammatory response link
coronary artery link artery wall link
Show evidence (6 references)
PMID:23188196 SUPPORT
"Kawasaki disease (KD) is considered to be a kind of systemic vasculitis syndrome. It most frequently affects infants and young children and primarily invades medium-sized muscular arteries, including the coronary arteries."
The literature confirms that Kawasaki disease involves widespread inflammation of medium-sized arteries, including coronary arteries.
PMID:31599798 SUPPORT
"Kawasaki disease is a childhood vasculitis of unknown origin, whose major complication is the development of coronary artery aneurysms (CAA)."
The literature supports that Kawasaki disease leads to vascular inflammation and aneurysm formation.
PMID:27090101 SUPPORT
"Coronary angiography showed multiple aneurysms which suggested sequelae of misdiagnosed Kawasaki disease."
The case report indicates that Kawasaki disease can lead to aneurysm formation as a result of vascular inflammation.
+ 3 more references
Immune Response Dysregulation
An abnormal immune response leading to vessel wall damage and inflammation.
CD8-positive, alpha-beta T cell link T-helper 17 cell link regulatory T cell link plasmablast link plasma cell link dendritic cell link
interleukin-1 beta production link tumor necrosis factor production link interleukin-17 production link calcium ion transmembrane transport link T cell activation link complement activation link
NLRP3 inflammasome complex link
Show evidence (4 references)
PMID:34890998 SUPPORT
"Increasing evidence shows that the pathogenesis of Kawasaki disease (KD) is caused by abnormal and unbalanced innate and adaptive immune responses."
The literature supports the statement that Kawasaki Disease is characterized by immune response dysregulation leading to vessel wall damage and inflammation.
PMID:30183655 SUPPORT
"Kawasaki disease (KD) is a vasculitis that is part of systemic vasculitis syndrome. It affects medium-sized vessels and is characterized by hypercytokinemia."
This reference supports that KD involves immune dysregulation leading to vessel wall damage.
PMID:30619331 SUPPORT
"Others have favored an autoreactive hypothesis that KD is triggered by an antigen that shares homology with structures in the vascular wall, and molecular mimicry resulting in an immune response directed to that tissue."
This supports the notion of an abnormal immune response leading to vessel wall damage in KD.
+ 1 more reference

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Kawasaki Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

40
Blood 2
Thrombocytosis VERY_FREQUENT Thrombocytosis (HP:0001894)
Often appears 1-2 weeks after onset
Show evidence (3 references)
PMID:33527178 SUPPORT
"In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute phase."
Thrombocytosis is a common finding during the subacute phase of KD.
PMID:6833960 SUPPORT
"The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash, joint manifestations, thrombocytosis, and cardiac disease."
Thrombocytosis occurs during the subacute phase of KD.
ORPHA:2331 PARTIAL
"HP:0001894 | Thrombocytosis | Frequent (79-30%)"
Orphanet classifies thrombocytosis as frequent (79-30%), while clinical consensus and this entry classify it as very frequent. Thrombocytosis is near-universal in the subacute phase.
Leukocytosis FREQUENT Increased total leukocyte count (HP:0001974)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0001974 | Leukocytosis | Frequent (79-30%)"
Orphanet classifies leukocytosis as frequent in Kawasaki disease.
Cardiovascular 9
Conjunctivitis VERY_FREQUENT Conjunctivitis (HP:0000509)
Non-purulent (no pus)
Show evidence (4 references)
PMID:34814144 SUPPORT
"In cross-sectional studies, KD was associated with allergic rhinitis (n = 6; OR, 1.69; 95% CI, 1.52-1.87), asthma (n = 3; OR, 1.72; 95% CI, 1.38-2.14), allergic conjunctivitis (n = 2; OR, 1.95; 95% CI, 1.68-2.27), and atopic dermatitis (n = 3; OR, 1.35; 95% CI, 1.22-1.49)."
The study shows that Kawasaki Disease is associated with allergic conjunctivitis, supporting the statement that conjunctivitis is very frequent in Kawasaki Disease.
PMID:32843441 SUPPORT
"Both patients presented with fever lasting >5 days and were found to have rash, conjunctival injection, and swollen lips."
The description of conjunctival injection in patients with Kawasaki Disease supports the statement.
PMID:7299613 SUPPORT
"In a prospective series, ophthalmologic examinations on 10 children with Kawasaki disease showed that eight had anterior uveitis during the acute phase of the illness."
Although the study focuses on anterior uveitis, it indicates significant ocular involvement in Kawasaki Disease, supporting the statement indirectly.
+ 1 more reference
Cervical Lymphadenopathy FREQUENT Cervical lymphadenopathy (HP:0025289)
Often unilateral presentation
Show evidence (2 references)
ORPHA:2331 PARTIAL
"HP:0025289 | Cervical lymphadenopathy | Very frequent (99-80%)"
Orphanet classifies cervical lymphadenopathy as very frequent (99-80%), but clinical series report it in 50-75% of cases, making it the least common of the five classic criteria. FREQUENT is retained based on published cohort data.
PMID:26631821 SUPPORT
"The main symptoms were fever (100%), exanthema (98%), changes in the extremities (91%), conjunctivitis (77%), oral cavity changes (89%), cervical adenitis (55%) and cardiac abnormalities (45%)."
Cervical adenitis was present in 55% of adult KD cases in this French cohort.
Myocarditis OCCASIONAL Myocarditis (HP:0012819)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0012819 | Myocarditis | Occasional (29-5%)"
Orphanet classifies myocarditis as occasional in Kawasaki disease.
PMID:9665974 SUPPORT
"Common cardiovascular manifestations of the illness include myocarditis, pericardial effusion, and coronary artery aneurysm formation."
Rowley and Shulman list myocarditis among common cardiovascular manifestations of Kawasaki syndrome.
Aneurysm Formation FREQUENT Vascular dilatation (HP:0002617)
Show evidence (2 references)
PMID:31599798 SUPPORT
"Kawasaki disease is a childhood vasculitis of unknown origin, whose major complication is the development of coronary artery aneurysms (CAA)."
This reference directly states that coronary artery aneurysm development is a major complication of Kawasaki disease.
PMID:21447126 SUPPORT
"Histologically, coronary arteritis begins 6-8 days after the onset of KD, and leads immediately to inflammation of all layers of the artery. The inflammation spreads completely around the artery; as a result, structural components of the artery undergo intense damage; the artery then begins to dilate."
This reference describes the mechanism by which arterial inflammation leads to dilation and aneurysm formation in Kawasaki disease.
Pericarditis FREQUENT Pericarditis (HP:0001701)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0001701 | Pericarditis | Frequent (79-30%)"
Orphanet classifies pericarditis as frequent in Kawasaki disease.
PMID:9665974 PARTIAL
"Common cardiovascular manifestations of the illness include myocarditis, pericardial effusion, and coronary artery aneurysm formation."
The snippet mentions pericardial effusion rather than pericarditis per se; pericardial effusion is a frequent accompaniment of pericarditis but they are distinct entities.
Arrhythmia OCCASIONAL Arrhythmia (HP:0011675)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0011675 | Arrhythmia | Occasional (29-5%)"
Orphanet classifies arrhythmia as occasional in Kawasaki disease.
Abnormal Heart Valve Morphology FREQUENT Abnormal heart valve morphology (HP:0001654)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0001654 | Abnormal heart valve morphology | Frequent (79-30%)"
Orphanet classifies abnormal heart valve morphology as frequent in Kawasaki disease.
Congestive Heart Failure OCCASIONAL Congestive heart failure (HP:0001635)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0001635 | Congestive heart failure | Occasional (29-5%)"
Orphanet classifies congestive heart failure as occasional in Kawasaki disease.
Vasculitis VERY_FREQUENT Vasculitis (HP:0002633)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0002633 | Vasculitis | Very frequent (99-80%)"
Orphanet classifies vasculitis as very frequent in Kawasaki disease, consistent with vasculitis being the defining pathological feature.
Digestive 4
Diarrhea FREQUENT Diarrhea (HP:0002014)
Temporal: ACUTE
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0002014 | Diarrhea | Frequent (79-30%)"
Orphanet classifies diarrhea as frequent in Kawasaki disease.
PMID:30029859 PARTIAL
"Fever, abdominal pain, and vomiting were the most frequent symptoms observed and typical Kawasaki disease signs and symptoms appeared after intestinal complaints in all cases."
The snippet documents GI involvement in KD but mentions abdominal pain and vomiting rather than diarrhea specifically.
Nausea and Vomiting OCCASIONAL Nausea and vomiting (HP:0002017)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0002017 | Nausea and vomiting | Occasional (29-5%)"
Orphanet classifies nausea and vomiting as occasional in Kawasaki disease.
Hepatitis OCCASIONAL Hepatitis (HP:0012115)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0012115 | Hepatitis | Occasional (29-5%)"
Orphanet classifies hepatitis as occasional in Kawasaki disease.
PMID:36557034 SUPPORT
"Out of these six KD patients, there were two patients complicated with hepatitis and one patient with gallbladder hydrops. Different clinical features including jaundice (n = 3) and hepatomegaly (n = 4) were also observed."
Case series confirms hepatitis and hepatomegaly as hepatobiliary complications of Kawasaki disease.
Jaundice OCCASIONAL Jaundice (HP:0000952)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0000952 | Jaundice | Occasional (29-5%)"
Orphanet classifies jaundice as occasional in Kawasaki disease.
PMID:36557034 SUPPORT
"Different clinical features including jaundice (n = 3) and hepatomegaly (n = 4) were also observed."
Jaundice was observed in KD patients with hepatobiliary manifestations.
Genitourinary 1
Proteinuria VERY_FREQUENT Proteinuria (HP:0000093)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0000093 | Proteinuria | Very frequent (99-80%)"
Orphanet classifies proteinuria as very frequent in Kawasaki disease.
PMID:27287282 SUPPORT
"Genitourinary involvement in patients with Kawasaki disease is typically limited to sterile pyuria and proteinuria."
Proteinuria is described as a typical genitourinary finding in Kawasaki disease.
Immune 2
Rash VERY_FREQUENT Skin rash (HP:0000988)
Show evidence (5 references)
PMID:26631821 SUPPORT
"The main symptoms were fever (100%), exanthema (98%)..."
Exanthema, which refers to a widespread rash, was present in 98% of the adult patients with Kawasaki Disease.
PMID:1440951 SUPPORT
"We describe a four-year-old girl who presented with fever, a diffuse erythematous maculopapular rash..."
The case description includes a diffuse erythematous maculopapular rash as one of the clinical features.
PMID:33453126 SUPPORT
"All children with KD have fever accompanied by clinical signs, with four of the five classic criteria for complete KD being mucocutaneous..."
The abstract emphasizes the mucocutaneous manifestations, which include skin rashes, as critical for diagnosing Kawasaki Disease.
+ 2 more references
Aseptic Meningitis OCCASIONAL Meningitis (HP:0001287)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0001287 | Meningitis | Occasional (29-5%)"
Orphanet classifies meningitis as occasional in Kawasaki disease.
PMID:33530798 SUPPORT
"Aseptic meningitis (AM) is an uncommon feature of KD."
Full-text directly characterizes aseptic meningitis as an uncommon but recognized feature of Kawasaki disease.
Metabolism 3
Fever VERY_FREQUENT Fever (HP:0001945)
Show evidence (4 references)
PMID:30029859 SUPPORT
"Fever, abdominal pain, and vomiting were the most frequent symptoms observed and typical Kawasaki disease signs and symptoms appeared after intestinal complaints in all cases."
The literature mentions fever as one of the most frequent symptoms observed in Kawasaki disease, supporting the statement that fever is a very frequent systemic diagnostic symptom of Kawasaki disease.
PMID:31900257 SUPPORT
"The conundrum for acute paediatricians is which clinical features best distinguish the febrile child with possible KD, needing intravenous immunoglobulin, from the many other children with febrile illnesses."
The literature highlights the challenge of distinguishing Kawasaki disease from other febrile illnesses, indicating that fever is a very frequent systemic diagnostic symptom in Kawasaki disease.
PMID:26631821 SUPPORT
"The main symptoms were fever (100%), exanthema (98%), changes in the extremities (91%), conjunctivitis (77%), oral cavity changes (89%), cervical adenitis (55%) and cardiac abnormalities (45%)."
The literature states that fever is present in 100% of the cases, supporting the statement that fever is a very frequent systemic diagnostic symptom of Kawasaki disease.
+ 1 more reference
Edema FREQUENT Edema (HP:0000969)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0000969 | Edema | Frequent (79-30%)"
Orphanet classifies edema as frequent in Kawasaki disease.
Hypoalbuminemia FREQUENT Hypoalbuminemia (HP:0003073)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0003073 | Hypoalbuminemia | Frequent (79-30%)"
Orphanet classifies hypoalbuminemia as frequent in Kawasaki disease.
Musculoskeletal 1
Arthritis FREQUENT Arthritis (HP:0001369)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0001369 | Arthritis | Frequent (79-30%)"
Orphanet classifies arthritis as frequent in Kawasaki disease.
PMID:31974671 PARTIAL
"Eight hundred sixty-five children (male:female 29:11) were diagnosed with KD during this period-of these, 40 (4.6%) had arthritis."
This cohort shows 4.6% incidence (OCCASIONAL range), while ORPHA classifies arthritis as frequent. The wide reported range (2-31%) across studies suggests variability in ascertainment.
Nervous System 2
Irritability OCCASIONAL Irritability (HP:0000737)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0000737 | Irritability | Occasional (29-5%)"
Orphanet classifies irritability as occasional in Kawasaki disease.
Cranial Nerve Paralysis OCCASIONAL Cranial nerve paralysis (HP:0006824)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0006824 | Cranial nerve paralysis | Occasional (29-5%)"
Orphanet classifies cranial nerve paralysis as occasional in Kawasaki disease.
PMID:31364426 SUPPORT
"Kawasaki disease (KD) is an acute multisystem vasculitic syndrome that predominantly affects infants and young children. Neurological complications are rare in patients with KD and the diagnosis is challenging."
Case report with literature review documents bilateral facial nerve palsy and meningitis as rare neurological complications of KD.
Respiratory 1
Pharyngitis VERY_FREQUENT Pharyngitis (HP:0025439)
Show evidence (1 reference)
ORPHA:2331 PARTIAL
"HP:0100776 | Recurrent pharyngitis | Very frequent (99-80%)"
Orphanet lists recurrent pharyngitis (HP:0100776) as very frequent, but KD pharyngitis is acute, not recurrent. HP:0025439 (Pharyngitis) is used here as the more accurate term. The frequency data supports pharyngeal involvement being very frequent.
Constitutional 3
Abdominal Pain FREQUENT Abdominal pain (HP:0002027)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0002027 | Abdominal pain | Frequent (79-30%)"
Orphanet classifies abdominal pain as frequent in Kawasaki disease.
PMID:30029859 SUPPORT
"Fever, abdominal pain, and vomiting were the most frequent symptoms observed and typical Kawasaki disease signs and symptoms appeared after intestinal complaints in all cases."
Abdominal pain is one of the most frequent gastrointestinal symptoms in Kawasaki disease.
Arthralgia OCCASIONAL Arthralgia (HP:0002829)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0002829 | Arthralgia | Occasional (29-5%)"
Orphanet classifies arthralgia as occasional in Kawasaki disease.
PMID:3333141 PARTIAL
"Peeling of skin of fingers and toes, arthralgia, and marked thrombocytosis are frequent 1-2 weeks after onset."
Arthralgia is described as frequent in this reference, while ORPHA classifies it as occasional (29-5%). The discrepancy may reflect differences in ascertainment criteria.
Fatigue FREQUENT Fatigue (HP:0012378)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0012378 | Fatigue | Frequent (79-30%)"
Orphanet classifies fatigue as frequent in Kawasaki disease.
Other 12
Swelling of Hands and Feet VERY_FREQUENT
Show evidence (2 references)
PMID:1704148 SUPPORT
"The six main clinical presentations of Kawasaki disease are: prolonged fever, conjunctivitis, lesions of the oral and pharyngeal mucosa, inflammatory reddening and swelling of the hands and feet, skin rash and cervical lymph node enlargement."
The literature explicitly mentions that swelling of the hands and feet is one of the six main clinical presentations of Kawasaki disease.
PMID:3333141 SUPPORT
"Early clinical features include fever, rash, conjunctival injection, dry reddened lips, oropharyngeal reddening, enlarged cervical nodes, and swelling and redness of hands and feet."
The literature lists swelling and redness of hands and feet as early clinical features of Kawasaki disease.
Coronary Artery Aneurysms OCCASIONAL
Can lead to serious heart complications
Show evidence (4 references)
PMID:10512599 REFUTE
"Coronary artery aneurysms or ectasia develop in approximately 15-25% of children with the disease."
The literature indicates that coronary artery aneurysms are a common complication of Kawasaki disease, occurring in 15-25% of cases, which is more frequent than 'occasional'.
PMID:31732547 REFUTE
"Twenty-three patients had SAAs, demonstrating an incidence of 14.2% (23 of 162) in patients who were screened at 1 month after onset. The proportion of patients with SAAs was estimated to be 2% (23 of 1148) of all patients with KD."
The incidence of coronary artery aneurysms (CAAs) in Kawasaki disease is significant, with a notable percentage of patients developing CAAs, indicating that the frequency is more than 'occasional'.
PMID:34651205 REFUTE
"Among the 640 KD children, most were 1-5 years old (415/640, 64.8%). Children < 1 year old (31.6%) and > 5 years old (28.3%) were more likely to have cardiovascular complications."
The study shows a high incidence of cardiovascular complications in children with Kawasaki disease, indicating that coronary artery aneurysms and other heart complications are not just occasional.
+ 1 more reference
Palmoplantar Erythema VERY_FREQUENT Palmoplantar erythema (HP:0025493)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0025493 | Palmoplantar erythema | Very frequent (99-80%)"
Orphanet classifies palmoplantar erythema as very frequent in Kawasaki disease.
Cheilitis VERY_FREQUENT Cheilitis (HP:0100825)
Show evidence (3 references)
ORPHA:2331 SUPPORT
"HP:0100825 | Cheilitis | Very frequent (99-80%)"
Orphanet classifies cheilitis as very frequent in Kawasaki disease.
PMID:1440951 SUPPORT
"We describe a four-year-old girl who presented with fever, a diffuse erythematous maculopapular rash, bilateral nonpurulent bulbar conjunctivitis, dry, red, fissured lips, a tongue with a strawberry 'appearance', an erythematous pharynx, indurative erythema, and edema and desquamation of the..."
Dry, red, fissured lips are described as a presenting feature of Kawasaki syndrome.
PMID:26631821 SUPPORT
"The main symptoms were fever (100%), exanthema (98%), changes in the extremities (91%), conjunctivitis (77%), oral cavity changes (89%), cervical adenitis (55%) and cardiac abnormalities (45%)."
Oral cavity changes (including lip involvement) were present in 89% of cases, supporting very frequent classification.
Strawberry Tongue FREQUENT Strawberry tongue (HP:0031042)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0031042 | Strawberry tongue | Frequent (79-30%)"
Orphanet classifies strawberry tongue as frequent in Kawasaki disease.
PMID:15835487 SUPPORT
"The disease can present with protean clinical manifestations which include high grade fever (for at least 5 days), rash, redness of the lips and a typical strawberry tongue, cervical lymph node enlargement (often unilateral), swelling over the hands/feet and, later a characteristic peripheral..."
Strawberry tongue is listed as a typical clinical manifestation of Kawasaki disease.
Glossitis FREQUENT Glossitis (HP:0000206)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0000206 | Glossitis | Frequent (79-30%)"
Orphanet classifies glossitis as frequent in Kawasaki disease.
Scaling Skin on Fingertip FREQUENT Scaling skin on fingertip (HP:0025525)
Particularly on the fingers and toes, often during the subacute phase
Show evidence (4 references)
ORPHA:2331 SUPPORT
"HP:0025525 | Scaling skin on fingertip | Frequent (79-30%)"
Orphanet classifies fingertip scaling as frequent in Kawasaki disease.
PMID:3333141 SUPPORT
"Peeling of skin of fingers and toes, arthralgia, and marked thrombocytosis are frequent 1-2 weeks after onset."
Peeling of fingers is described as frequent 1-2 weeks after onset of Kawasaki disease.
PMID:6833960 SUPPORT
"The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash..."
Desquamation is a frequent dermatologic manifestation during the subacute phase of Kawasaki disease.
+ 1 more reference
Abnormality of Nail Color FREQUENT Abnormality of nail color (HP:0100643)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0100643 | Abnormality of nail color | Frequent (79-30%)"
Orphanet classifies nail color abnormalities as frequent in Kawasaki disease.
Palmar Edema FREQUENT Palmar edema (HP:0025538)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0025538 | Palmar edema | Frequent (79-30%)"
Orphanet classifies palmar edema as frequent in Kawasaki disease.
Plantar Edema FREQUENT Plantar edema (HP:0025537)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0025537 | Plantar edema | Frequent (79-30%)"
Orphanet classifies plantar edema as frequent in Kawasaki disease.
Cholecystitis OCCASIONAL Cholecystitis (HP:0001082)
Show evidence (1 reference)
ORPHA:2331 SUPPORT
"HP:0001082 | Cholecystitis | Occasional (29-5%)"
Orphanet classifies cholecystitis as occasional in Kawasaki disease.
Sterile Pyuria OCCASIONAL Sterile pyuria (HP:0100586)
Show evidence (2 references)
ORPHA:2331 SUPPORT
"HP:0100586 | Sterile pyuria | Occasional (29-5%)"
Orphanet classifies sterile pyuria as occasional in Kawasaki disease.
PMID:23390440 SUPPORT
"Kawasaki disease (KD) is a systemic vasculitis and affects many organ systems. It often presents sterile pyuria, microscopic hematuria, and proteinuria due to renal involvement."
Sterile pyuria is a recognized renal manifestation of Kawasaki disease.
🧬

Genetic Associations

21
ITPKC (Risk variant reduces negative regulation of Ca2+/NFAT signaling leading to enhanced T-cell activation)
FCGR2A (Mediates immune-complex driven neutrophil/monocyte activation)
FCGR3A (Mediates immune-complex driven neutrophil/monocyte activation)
BLK (B lymphoid tyrosine kinase involved in B-cell receptor signaling)
CD40 (Promotes B/T cell and endothelial activation via CD40-CD40L co-stimulation)
HLA-B (HLA associations support antigen-driven or superantigen-like T-cell responses)
CASP3 (Implicated in endothelial cell apoptosis and vascular remodeling during acute vasculitis)
ORAI1 (Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling)
STIM1 (Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling)
TGFBR2 (TGF-β receptor involved in endothelial-to-mesenchymal transition)
SMAD3 (TGF-β signaling mediator involved in vascular remodeling)
TGFB2 (TGF-β signaling involved in chronic vascular remodeling)
IL1B (IL-1β promotes endothelial injury, inflammation and remodeling)
IL1R1 (IL-1 receptor; downstream of inflammasome activation)
TNF (Induces endothelial cell expression of ICAM-1/VCAM-1, iNOS and proinflammatory cascade)
IL17A (Th17 expansion and elevated IL-17 associate with coronary damage and IVIG resistance)
IL23A (IL-23 involved in Th17 axis and IL-17 signaling)
NLRP3 (NLRP3 inflammasome activation leads to IL-1β release and pyroptosis)
NOS3 (Reduced eNOS expression/activity leads to decreased NO, vasoconstriction, and thrombosis)
ICAM1 (Upregulated by TNF/IL-1 leading to leukocyte recruitment and endothelial dysfunction)
VCAM1 (Upregulated by TNF/IL-1 leading to vascular injury)
💊

Treatments

6
Intravenous Immunoglobulin (IVIG)
Action: intravenous immunoglobulin therapy Ontology label: immunoglobulin infusion therapy MAXO:0001480
First-line treatment to reduce inflammation and risk of coronary artery complications.
Show evidence (5 references)
PMID:23283289 SUPPORT
"Intravenous immunoglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease."
The literature confirms that IVIG is part of the standard initial therapy for Kawasaki disease, aimed at reducing inflammation and preventing coronary artery complications.
PMID:38135926 SUPPORT
"For KD patients, male, children aged 3 to 9 years, and those with fever longer than 6 days before intravenous immunoglobulin (IVIG) use were more likely to have CAL."
The study discusses the use of IVIG and its timing in relation to the risk of coronary artery lesions, supporting its role in reducing such risks.
PMID:24034380 SUPPORT
"The standard of care for treatment is intravenous immunoglobulin plus aspirin, but adding corticosteroids may provide additional benefit for high-risk patients."
The literature states that IVIG is the standard of care for treating Kawasaki disease to reduce coronary artery complications.
+ 2 more references
Aspirin
Action: cardiovascular agent therapy MAXO:0000181
Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots.
Show evidence (4 references)
PMID:9513217 SUPPORT
"Treatment includes the hospitalization of the child and subsequent administration of high doses of aspirin and intravenous immunoglobulin. With recovery, aspirin doses are reduced and the child may be monitored at home with outpatient follow-up."
This reference confirms that high doses of aspirin are used initially for Kawasaki disease, followed by lower doses after recovery.
PMID:10935427 SUPPORT
"Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose until the fourteenth day of illness then low dose)."
This reference also supports the statement that high doses of aspirin are used initially, followed by lower doses.
PMID:32159800 PARTIAL
"Low-dose aspirin plus IVIG might be as effective as high-dose aspirin plus IVIG for the initial treatment of Kawasaki disease. Considering that high-dose aspirin may cause more adverse reactions than low-dose aspirin, low-dose aspirin plus IVIG should be recommended as the first-line therapy in..."
This reference suggests that low-dose aspirin might be equally effective as high-dose aspirin and should be recommended to avoid adverse reactions, indicating a shift in treatment preference.
+ 1 more reference
Anakinra
Action: Pharmacotherapy NCIT:C15986
Agent: anakinra
IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury.
Cyclosporine
Action: Pharmacotherapy NCIT:C15986
Agent: cyclosporine
Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients.
Corticosteroids
Action: systemic corticosteroid therapy Ontology label: Systemic Corticosteroid Therapy NCIT:C122080
Used in cases resistant to IVIG or with severe inflammation.
Show evidence (3 references)
PMID:31914832 SUPPORT
"We suggest using methylprednisolone pulse therapy as an alternative rescue therapy for immunoglobulin-resistant KD, as well as identifying high-risk patients who need initial corticosteroid with IVIG treatment with an adequate route, dose, and duration."
The literature supports the use of corticosteroids in cases of Kawasaki Disease that are resistant to IVIG or in high-risk patients with severe inflammation.
PMID:29101553 SUPPORT
""Resistant" Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some..."
This reference discusses the management of resistant Kawasaki Disease, which includes considering corticosteroid use.
PMID:33541111 SUPPORT
"To prevent CAA, more intensified or adjunctive therapies using other agents, such as pulsed methylprednisolone, ciclosporin, infliximab, and Anakinra, should be considered for patients with these risk factors."
This reference mentions the use of pulsed methylprednisolone (a corticosteroid) for patients with Kawasaki Disease who are at risk of developing coronary artery abnormalities, indicating severe inflammation.
Infliximab
Action: Pharmacotherapy NCIT:C15986
Agent: infliximab
Anti-TNF monoclonal antibody used for IVIG-resistant Kawasaki disease to block TNF-mediated endothelial activation and inflammation.
Show evidence (1 reference)
PMID:33541111 SUPPORT
"To prevent CAA, more intensified or adjunctive therapies using other agents, such as pulsed methylprednisolone, ciclosporin, infliximab, and Anakinra, should be considered for patients with these risk factors."
Infliximab is listed among adjunctive therapies for IVIG-resistant KD patients at risk of coronary artery abnormalities.
🔬

Biochemical Markers

3
C-Reactive Protein (CRP) (Elevated)
Context: Indicator of inflammation
Show evidence (4 references)
PMID:34078404 SUPPORT
"CAL were found in 12.9 and 18.3% of the high and low CRP patients, respectively (p < 0.001), based on z-scores; and in 9.9 and 12.5%, respectively (p = 0.001), based on the Japanese criteria in the acute phase."
The study indicates that CRP levels are elevated in Kawasaki Disease patients, with specific percentages of high and low CRP levels noted.
PMID:39117827 SUPPORT
"Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy."
The abstract describes KD as a hyperinflammatory syndrome, implying elevated inflammatory markers such as CRP.
PMID:37551875 SUPPORT
"Complete blood count, C-reactive protein (CRP), liver and renal function tests, serum electrolytes, chest X-ray, NT-proBNP level, Bactec blood culture, urine microscopy and culture along with detailed physical examination was done for all cases and control."
The study includes CRP as part of the diagnostic tests for Kawasaki Disease, indicating its relevance as an inflammatory marker.
+ 1 more reference
Erythrocyte Sedimentation Rate (ESR) (Elevated)
Context: Indicator of inflammation
Show evidence (3 references)
PMID:36604937 SUPPORT
"NLR >/=2.08 was 82% sensitive and 80% specific in predicting CAL. ESR >/=88 mm/h was 85% sensitive and 64% specific in predicting IVIg resistance."
The study indicates that ESR is elevated in Kawasaki Disease and can be used to predict IVIg resistance.
PMID:33413220 SUPPORT
"In comparison between KDSS and TSS, patients with KDSS had a significantly higher erythrocyte sedimentation rate (ESR) and significantly lower creatinine."
The study shows that patients with Kawasaki Disease Shock Syndrome (KDSS) have significantly higher ESR levels.
PMID:15677370 SUPPORT
"The erythrocyte sedimentation rate (ESR) increased significantly 24 h after IVIG, and the elevated level was sustained for 7 days."
This reference shows that ESR levels are elevated during the acute stage of Kawasaki Disease.
Platelet Count (Elevated)
Context: Often seen in the subacute phase
Show evidence (2 references)
PMID:33527178 SUPPORT
"In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute phase."
The abstract states that thrombocytosis (elevated platelet count) is commonly found in the subacute phase of Kawasaki disease.
PMID:6833960 SUPPORT
"The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash, joint manifestations, thrombocytosis, and cardiac disease."
The text explicitly mentions that thrombocytosis occurs during the subacute phase of Kawasaki disease.
{ }

Source YAML

click to show
name: Kawasaki Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-30T12:00:00Z'
description: Kawasaki Disease is a condition in children that involves
  inflammation of blood vessels throughout the body and is characterized by
  fever, rash, and other symptoms.
category: Pediatric Condition
parents:
- Vasculitis
inheritance:
- name: Polygenic inheritance
  inheritance_term:
    preferred_term: Polygenic inheritance
    term:
      id: HP:0010982
      label: Polygenic inheritance
  description: >
    Kawasaki disease has a multigenic/multifactorial inheritance pattern with
    susceptibility loci identified in ITPKC, FCGR2A, BLK, CD40, CASP3, and
    HLA regions.
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "Multigenic/multifactorial"
    explanation: Orphanet classifies the inheritance pattern of Kawasaki disease
      as multigenic/multifactorial.
prevalence:
- population: Children under 5
  percentage: Rare
  evidence:
  - reference: PMID:10392592
    reference_title: "Kawasaki disease."
    supports: REFUTE
    snippet: Most children who contract this illness are less than two years old, and 80 percent of affected children are younger than five years of age.
    explanation: The statement that Kawasaki disease is rare in children under 5 is refuted by the literature, which indicates that 80% of affected children are younger than five years of age.
  - reference: PMID:36611091
    reference_title: "Epidemiology and risk factors for resistance to treatment of Kawasaki disease in Cyprus."
    supports: REFUTE
    snippet: 83% of patients were < 5 years of age and 10% were < 6 months.
    explanation: The study shows that a significant proportion of Kawasaki
      disease cases occur in children under 5 years of age, refuting the
      statement that it is rare in this population.
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "Unknown | Worldwide | Point prevalence | ORPHANET"
    explanation: Orphanet classifies the worldwide point prevalence as unknown,
      reflecting the variability in incidence across populations (highest in
      Japan and East Asia).
progression:
- phase: Onset
  age_range: 6 months to 5 years
  notes: Sudden onset with high fever
  evidence:
  - reference: PMID:36472296
    reference_title: "A CASE OF KAWASAKI DISEASE IN AN EIGHT-YEAR-OLD BOY."
    supports: PARTIAL
    snippet: Given the variety and inconsistency of the clinical symptoms (the child had four of the five mandatory criteria together with prolonged fever), there was a late diagnosis, namely on day 10 of the disease.
    explanation: This reference mentions prolonged fever as a symptom of Kawasaki Disease but does not specify the sudden onset of high fever.
  - reference: PMID:34459958
    reference_title: "Kawasaki disease in children younger than 6 months of age: characteristics of a Spanish cohort."
    supports: PARTIAL
    snippet: A retrospective study that compared children younger than 6 months versus older children of a Spanish cohort of patients diagnosed with Kawasaki disease between 2011 and 2016 (Kawa-Race study).
    explanation: This reference provides information on Kawasaki Disease in children younger than 6 months and older but does not specifically mention the age range of 6 months to 5 years or the sudden onset with high fever.
  - reference: PMID:37553209
    reference_title: "Rising Kawasaki disease incidence in New Zealand: analysis of national population incidence and outcomes 2000-2017."
    supports: PARTIAL
    snippet: The mean age was 39.8 months (SD 37) and 592 (59%) were boys.
    explanation: This reference indicates that the mean age of Kawasaki Disease patients was within the 6 months to 5 years range but does not specifically mention the sudden onset with high fever.
  - reference: PMID:31910632
    reference_title: "Japanese Kawasaki Disease Scoring Systems: Are they Applicable to the Iranian Population?"
    supports: PARTIAL
    snippet: Kawasaki disease (KD) is the most frequent cause of coronary artery aneurysm (CAA) in children.
    explanation: This reference focuses on coronary artery aneurysm in children with Kawasaki Disease but does not provide specific details about the age range or the sudden onset with high fever.
  - reference: PMID:36611091
    reference_title: "Epidemiology and risk factors for resistance to treatment of Kawasaki disease in Cyprus."
    supports: PARTIAL
    snippet: 83% of patients were < 5 years of age and 10% were < 6 months.
    explanation: This reference mentions that 83% of Kawasaki Disease patients were under 5 years of age but does not specify the sudden onset with high fever.
- phase: Acute
  duration: 1-2 weeks
  notes: High fever, rash, conjunctivitis, swollen hands and feet
  evidence:
  - reference: PMID:9665974
    reference_title: "Kawasaki syndrome."
    supports: PARTIAL
    snippet: The illness is manifested by prolonged fever, conjunctival injection, enanthem, exanthem, erythema and swelling of the hands and feet, and cervical adenopathy. These acute features of illness are self-limiting.
    explanation: The reference confirms the symptoms mentioned in the statement (high fever, rash, conjunctivitis, swollen hands and feet) during the acute phase of Kawasaki Disease. However, it does not specify the exact duration of 1-2 weeks.
  - reference: PMID:31974671
    reference_title: "Clinico-laboratory profile of Kawasaki disease with arthritis in children."
    supports: PARTIAL
    snippet: Arthritis in KD is usually non-erosive, self-limiting, and responds well to a short course of NSAIDs.
    explanation: The reference mentions that arthritis in KD is self-limiting, which implies a limited duration. However, it does not explicitly confirm the 1-2 week duration for the acute phase.
  - reference: PMID:39117827
    reference_title: "Kawasaki Disease-Associated Cytokine Storm Syndrome."
    supports: PARTIAL
    snippet: Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy.
    explanation: The reference confirms the symptoms mentioned in the statement during the acute phase of Kawasaki Disease. However, it does not specify the exact duration of 1-2 weeks.
- phase: Subacute
  duration: 2-4 weeks
  notes: Peeling skin, joint pain, possible coronary artery changes
  evidence:
  - reference: PMID:28580712
    reference_title: "Kawasaki disease: State of the art."
    supports: PARTIAL
    snippet: Kawasaki disease begins as a necrotizing arteritis with neutrophilic infiltrate, followed by subacute/chronic changes and luminal myofibroblastic proliferation that can cause coronary artery stenosis.
    explanation: This reference mentions the subacute phase and coronary artery changes but does not specify the duration of 2-4 weeks or mention peeling skin and joint pain.
  - reference: PMID:33453126
    reference_title: "Kawasaki disease for the paediatric dermatologist: skin manifestations and new insights into the pathophysiology."
    supports: PARTIAL
    snippet: All children with KD have fever accompanied by clinical signs, with four of the five classic criteria for complete KD being mucocutaneous, thus creating an important role for dermatologists.
    explanation: This reference discusses skin manifestations, which could include peeling, but does not specify the subacute phase duration or joint pain.
- phase: Convalescent
  duration: 6-8 weeks
  notes: Symptoms resolve, but coronary artery abnormalities may persist
  evidence:
  - reference: PMID:28580712
    reference_title: "Kawasaki disease: State of the art."
    supports: PARTIAL
    snippet: Kawasaki disease is an acute febrile arteritis of childhood that can result in coronary artery aneurysms if untreated in the first 10 and ideally 7 days of illness. Kawasaki disease begins as a necrotizing arteritis with neutrophilic infiltrate, followed by subacute/chronic changes and luminal myofibroblastic proliferation that can cause coronary artery stenosis.
    explanation: The literature indicates that Kawasaki disease can lead to coronary artery abnormalities, but it does not specify that the convalescent phase lasts 6-8 weeks. It supports the persistence of coronary artery abnormalities but does not confirm the exact duration of the convalescent phase.
  - reference: PMID:17033807
    reference_title: "Predictive risk factors for coronary artery abnormalities in Kawasaki disease."
    supports: PARTIAL
    snippet: Conclusively, the most important predictor of CAA in KD is total duration of fever longer than 8 days. Early identification of IVGG non-responders and active therapeutic intervention for fever in KD cases might decrease the incidence of CAA.
    explanation: This reference discusses the importance of early intervention to prevent coronary artery abnormalities but does not provide specific information about the duration of the convalescent phase.
  - reference: PMID:29437127
    reference_title: "Kawasaki Disease."
    supports: NO_EVIDENCE
    snippet: Kawasaki Disease.
    explanation: This reference does not provide specific information about the duration of the convalescent phase or the persistence of coronary artery abnormalities.
pathophysiology:
- name: Vascular Inflammation
  description: Widespread inflammation of medium-sized arteries, including coronary arteries.
  cell_types:
  - preferred_term: vascular endothelial cell
    description: Primary target cells undergoing activation and dysfunction
    term:
      id: CL:0000071
      label: blood vessel endothelial cell
  - preferred_term: neutrophil
    description: Recruited to vessel walls during necrotizing arteritis phase
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: monocyte
    description: Activated by immune complexes and FcγR signaling
    term:
      id: CL:0000576
      label: monocyte
  - preferred_term: macrophage
    description: Present in coronary lesions producing cytokines
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: endothelial cell activation
    description: Cytokine-driven upregulation of adhesion molecules and inflammatory mediators
    term:
      id: GO:0042118
      label: endothelial cell activation
  - preferred_term: leukocyte adhesion to vascular endothelial cell
    description: ICAM-1/VCAM-1 mediated leukocyte recruitment
    term:
      id: GO:1904996
      label: positive regulation of leukocyte adhesion to vascular endothelial cell
  - preferred_term: inflammatory response
    description: Systemic hyperinflammatory syndrome with cytokine cascades
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: coronary artery
    description: Primary site of arteritis and aneurysm formation
    term:
      id: UBERON:0001621
      label: coronary artery
  - preferred_term: artery wall
    description: All three layers (intima, media, adventitia) undergo inflammation
    term:
      id: UBERON:0000415
      label: artery wall
  downstream:
  - target: Aneurysm Formation
    description: Coronary arteritis causes structural damage to arterial walls leading to dilation and aneurysm formation.
    evidence:
    - reference: PMID:21447126
      reference_title: "Pathogenesis of Kawasaki disease."
      supports: SUPPORT
      snippet: Histologically, coronary arteritis begins 6-8 days after the onset of KD, and leads immediately to inflammation of all layers of the artery. The inflammation spreads completely around the artery; as a result, structural components of the artery undergo intense damage; the artery then begins to dilate.
      explanation: This reference directly establishes the mechanistic link between coronary arteritis and aneurysm formation through structural damage.
  evidence:
  - reference: PMID:23188196
    reference_title: "Kawasaki disease: basic and pathological findings."
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is considered to be a kind of systemic vasculitis syndrome. It most frequently affects infants and young children and primarily invades medium-sized muscular arteries, including the coronary arteries.
    explanation: The literature confirms that Kawasaki disease involves widespread inflammation of medium-sized arteries, including coronary arteries.
  - reference: PMID:31599798
    reference_title: "One year in review: Kawasaki disease."
    supports: SUPPORT
    snippet: Kawasaki disease is a childhood vasculitis of unknown origin, whose major complication is the development of coronary artery aneurysms (CAA).
    explanation: The literature supports that Kawasaki disease leads to vascular inflammation and aneurysm formation.
  - reference: PMID:27090101
    reference_title: "[Coronary artery aneurysms probably due to Kawasaki's disease]."
    supports: SUPPORT
    snippet: Coronary angiography showed multiple aneurysms which suggested sequelae of misdiagnosed Kawasaki disease.
    explanation: The case report indicates that Kawasaki disease can lead to aneurysm formation as a result of vascular inflammation.
  - reference: PMID:36102118
    reference_title: "Long-term vascular dysfunction in Kawasaki disease: systematic review and meta-analyses."
    supports: SUPPORT
    snippet: Long-term physiological dysfunction in coronary/systemic vasculature may persist in individuals with Kawasaki disease even in the absence of coronary artery abnormalities.
    explanation: The literature suggests long-term vascular dysfunction due to Kawasaki disease, supporting the idea of widespread vascular inflammation.
  - reference: PMID:35420684
    reference_title: "Silent Kawasaki Disease Affecting Multiple Coronary Arteries in a 39-Year-Old Egyptian Woman."
    supports: SUPPORT
    snippet: Kawasaki disease, an acute febrile illness, can cause vasculitis in the coronary arteries.
    explanation: The literature confirms that Kawasaki disease causes inflammation in coronary arteries, leading to complications such as aneurysms.
  - reference: PMID:16990356
    reference_title: "The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases."
    supports: SUPPORT
    snippet: Kawasaki disease is an acute inflammatory syndrome that takes the form of systemic vasculitis, and predominantly affects children. Important complications of this disease are coronary artery dilation and aneurysm formation.
    explanation: The literature supports the statement that Kawasaki disease involves widespread vascular inflammation and aneurysm formation.
- name: Immune Response Dysregulation
  description: An abnormal immune response leading to vessel wall damage and inflammation.
  cell_types:
  - preferred_term: CD8-positive, alpha-beta T cell
    description: CD8+ T cells present in coronary lesions
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  - preferred_term: T-helper 17 cell
    description: Th17 expansion associated with coronary damage and IVIG resistance
    term:
      id: CL:0000899
      label: T-helper 17 cell
  - preferred_term: regulatory T cell
    description: Treg imbalance contributes to immune dysregulation
    term:
      id: CL:0000815
      label: regulatory T cell
  - preferred_term: plasmablast
    description: Convergent antigen-driven plasmablast responses in some patients
    term:
      id: CL:0000980
      label: plasmablast
  - preferred_term: plasma cell
    description: IgA plasma cells found in coronary lesions
    term:
      id: CL:0000786
      label: plasma cell
  - preferred_term: dendritic cell
    description: Involved in antigen presentation and T-cell activation
    term:
      id: CL:0000451
      label: dendritic cell
  biological_processes:
  - preferred_term: interleukin-1 beta production
    description: IL-1β promotes endothelial injury and inflammation
    term:
      id: GO:0032611
      label: interleukin-1 beta production
  - preferred_term: tumor necrosis factor production
    description: TNF-α induces endothelial activation and NF-κB signaling
    term:
      id: GO:0032640
      label: tumor necrosis factor production
  - preferred_term: interleukin-17 production
    description: IL-17 from Th17 cells promotes neutrophil recruitment
    term:
      id: GO:0032620
      label: interleukin-17 production
  - preferred_term: calcium ion transmembrane transport
    description: Dysregulated Ca2+/calcineurin-NFAT signaling pathway
    term:
      id: GO:0070588
      label: calcium ion transmembrane transport
  - preferred_term: T cell activation
    description: Enhanced T-cell activation via CD40-CD40L co-stimulation
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: complement activation
    description: Complement fixation contributes to vascular injury
    term:
      id: GO:0006956
      label: complement activation
  cellular_components:
  - preferred_term: NLRP3 inflammasome complex
    term:
      id: GO:0072559
      label: NLRP3 inflammasome complex
  evidence:
  - reference: PMID:34890998
    reference_title: "Atlas of circulating immune cells in Kawasaki disease."
    supports: SUPPORT
    snippet: Increasing evidence shows that the pathogenesis of Kawasaki disease (KD) is caused by abnormal and unbalanced innate and adaptive immune responses.
    explanation: The literature supports the statement that Kawasaki Disease is characterized by immune response dysregulation leading to vessel wall damage and inflammation.
  - reference: PMID:30183655
    reference_title: "Autoimmune Aspects of Kawasaki Disease."
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a vasculitis that is part of systemic vasculitis syndrome. It affects medium-sized vessels and is characterized by hypercytokinemia.
    explanation: This reference supports that KD involves immune dysregulation leading to vessel wall damage.
  - reference: PMID:30619331
    reference_title: "How Should We Classify Kawasaki Disease?"
    supports: SUPPORT
    snippet: Others have favored an autoreactive hypothesis that KD is triggered by an antigen that shares homology with structures in the vascular wall, and molecular mimicry resulting in an immune response directed to that tissue.
    explanation: This supports the notion of an abnormal immune response leading to vessel wall damage in KD.
  - reference: PMID:39117827
    reference_title: "Kawasaki Disease-Associated Cytokine Storm Syndrome."
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy.
    explanation: This reference supports the statement by describing KD as a hyperinflammatory syndrome, which involves immune dysregulation.
phenotypes:
- category: Systemic
  name: Fever
  description: High fever lasting at least 5 days, a mandatory criterion for diagnosis of Kawasaki disease.
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:30029859
    reference_title: "Intestinal Involvement in Kawasaki Disease."
    supports: SUPPORT
    snippet: Fever, abdominal pain, and vomiting were the most frequent symptoms observed and typical Kawasaki disease signs and symptoms appeared after intestinal complaints in all cases.
    explanation: The literature mentions fever as one of the most frequent symptoms observed in Kawasaki disease, supporting the statement that fever is a very frequent systemic diagnostic symptom of Kawasaki disease.
  - reference: PMID:31900257
    reference_title: "Fifteen-minute consultation: Kawasaki disease: how to distinguish from other febrile illnesses: tricks and tips."
    supports: SUPPORT
    snippet: The conundrum for acute paediatricians is which clinical features best distinguish the febrile child with possible KD, needing intravenous immunoglobulin, from the many other children with febrile illnesses.
    explanation: The literature highlights the challenge of distinguishing Kawasaki disease from other febrile illnesses, indicating that fever is a very frequent systemic diagnostic symptom in Kawasaki disease.
  - reference: PMID:26631821
    reference_title: "Kawasaki disease in adults: Observations in France and literature review."
    supports: SUPPORT
    snippet: The main symptoms were fever (100%), exanthema (98%), changes in
      the extremities (91%), conjunctivitis (77%), oral cavity changes (89%),
      cervical adenitis (55%) and cardiac abnormalities (45%).
    explanation: The literature states that fever is present in 100% of the
      cases, supporting the statement that fever is a very frequent systemic
      diagnostic symptom of Kawasaki disease.
  - reference: ORPHA:2331
    supports: PARTIAL
    snippet: "HP:0001945 | Fever | Frequent (79-30%)"
    explanation: Orphanet classifies fever as frequent (79-30%), but clinical
      data consistently shows fever in virtually 100% of cases and it is a
      mandatory diagnostic criterion. The VERY_FREQUENT classification is
      supported by multiple clinical cohort studies.
  phenotype_term:
    preferred_term: Fever
    description: Elevated body temperature above the normal range, typically above 38°C (100.4°F).
    term:
      id: HP:0001945
      label: Fever
- category: Dermatologic
  name: Rash
  description: Polymorphous exanthem typically affecting the trunk and extremities, without vesicles or crusting.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26631821
    reference_title: "Kawasaki disease in adults: Observations in France and literature review."
    supports: SUPPORT
    snippet: The main symptoms were fever (100%), exanthema (98%)...
    explanation: Exanthema, which refers to a widespread rash, was present in 98% of the adult patients with Kawasaki Disease.
  - reference: PMID:1440951
    reference_title: "Kawasaki syndrome."
    supports: SUPPORT
    snippet: We describe a four-year-old girl who presented with fever, a diffuse erythematous maculopapular rash...
    explanation: The case description includes a diffuse erythematous maculopapular rash as one of the clinical features.
  - reference: PMID:33453126
    reference_title: "Kawasaki disease for the paediatric dermatologist: skin manifestations and new insights into the pathophysiology."
    supports: SUPPORT
    snippet: All children with KD have fever accompanied by clinical signs, with four of the five classic criteria for complete KD being mucocutaneous...
    explanation: The abstract emphasizes the mucocutaneous manifestations, which include skin rashes, as critical for diagnosing Kawasaki Disease.
  - reference: PMID:23481152
    reference_title: "Incomplete Kawasaki disease."
    supports: SUPPORT
    snippet: This is a report of a 4-year-old Hispanic boy who presented with skin changes to the lips and oral cavity, a generalized rash...
    explanation: The case report mentions a generalized rash as one of the symptoms of Kawasaki Disease.
  - reference: PMID:32843441
    reference_title: "COVID-19 Inflammatory Syndrome With Clinical Features Resembling Kawasaki Disease."
    supports: SUPPORT
    snippet: Both patients presented with fever lasting >5 days and were found to have rash, conjunctival injection, and swollen lips.
    explanation: The patients with COVID-19 inflammatory syndrome had clinical features resembling Kawasaki Disease, including a rash.
  phenotype_term:
    preferred_term: Skin rash
    description: Visible change in skin color or texture, typically involving erythema or papules.
    term:
      id: HP:0000988
      label: Skin rash
- category: Ocular
  name: Conjunctivitis
  description: Bilateral bulbar conjunctival injection without exudate, typically limbal sparing.
  frequency: VERY_FREQUENT
  notes: Non-purulent (no pus)
  evidence:
  - reference: PMID:34814144
    reference_title: "Kawasaki Disease and Atopic Diseases: A Systematic Review and Meta-Analysis of Observational Studies."
    supports: SUPPORT
    snippet: In cross-sectional studies, KD was associated with allergic rhinitis (n = 6; OR, 1.69; 95% CI, 1.52-1.87), asthma (n = 3; OR, 1.72; 95% CI, 1.38-2.14), allergic conjunctivitis (n = 2; OR, 1.95; 95% CI, 1.68-2.27), and atopic dermatitis (n = 3; OR, 1.35; 95% CI, 1.22-1.49).
    explanation: The study shows that Kawasaki Disease is associated with allergic conjunctivitis, supporting the statement that conjunctivitis is very frequent in Kawasaki Disease.
  - reference: PMID:32843441
    reference_title: "COVID-19 Inflammatory Syndrome With Clinical Features Resembling Kawasaki Disease."
    supports: SUPPORT
    snippet: Both patients presented with fever lasting >5 days and were found to have rash, conjunctival injection, and swollen lips.
    explanation: The description of conjunctival injection in patients with Kawasaki Disease supports the statement.
  - reference: PMID:7299613
    reference_title: "Eye involvement in Kawasaki disease."
    supports: SUPPORT
    snippet: In a prospective series, ophthalmologic examinations on 10 children
      with Kawasaki disease showed that eight had anterior uveitis during the
      acute phase of the illness.
    explanation: Although the study focuses on anterior uveitis, it indicates
      significant ocular involvement in Kawasaki Disease, supporting the
      statement indirectly.
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0000509 | Conjunctivitis | Very frequent (99-80%)"
    explanation: Orphanet classifies conjunctivitis as very frequent in Kawasaki
      disease, consistent with it being one of the five classic diagnostic criteria.
  phenotype_term:
    preferred_term: Conjunctivitis
    description: Inflammation of the conjunctiva resulting in redness and irritation of the eye.
    term:
      id: HP:0000509
      label: Conjunctivitis
- category: Musculoskeletal
  name: Swelling of Hands and Feet
  description: Acute erythema and induration of the hands and feet with subsequent periungual desquamation.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:1704148
    reference_title: "[Kawasaki disease]."
    supports: SUPPORT
    snippet: 'The six main clinical presentations of Kawasaki disease are: prolonged fever, conjunctivitis, lesions of the oral and pharyngeal mucosa, inflammatory reddening and swelling of the hands and feet, skin rash and cervical lymph node enlargement.'
    explanation: The literature explicitly mentions that swelling of the hands and feet is one of the six main clinical presentations of Kawasaki disease.
  - reference: PMID:3333141
    reference_title: "Pathological features of Kawasaki disease (mucocutaneous lymph node syndrome)."
    supports: SUPPORT
    snippet: Early clinical features include fever, rash, conjunctival
      injection, dry reddened lips, oropharyngeal reddening, enlarged cervical
      nodes, and swelling and redness of hands and feet.
    explanation: The literature lists swelling and redness of hands and feet as
      early clinical features of Kawasaki disease.
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Coronary Artery Aneurysms
  description: Abnormal dilation of coronary arteries that can lead to thrombosis, stenosis, and myocardial infarction.
  notes: Can lead to serious heart complications
  evidence:
  - reference: PMID:10512599
    reference_title: "Kawasaki disease."
    supports: REFUTE
    snippet: Coronary artery aneurysms or ectasia develop in approximately 15-25% of children with the disease.
    explanation: The literature indicates that coronary artery aneurysms are a common complication of Kawasaki disease, occurring in 15-25% of cases, which is more frequent than 'occasional'.
  - reference: PMID:31732547
    reference_title: "Systemic Artery Aneurysms and Kawasaki Disease."
    supports: REFUTE
    snippet: Twenty-three patients had SAAs, demonstrating an incidence of 14.2% (23 of 162) in patients who were screened at 1 month after onset. The proportion of patients with SAAs was estimated to be 2% (23 of 1148) of all patients with KD.
    explanation: The incidence of coronary artery aneurysms (CAAs) in Kawasaki disease is significant, with a notable percentage of patients developing CAAs, indicating that the frequency is more than 'occasional'.
  - reference: PMID:34651205
    reference_title: "Analysis of multiple organ involvement in Kawasaki disease."
    supports: REFUTE
    snippet: Among the 640 KD children, most were 1-5 years old (415/640, 64.8%). Children < 1 year old (31.6%) and > 5 years old (28.3%) were more likely to have cardiovascular complications.
    explanation: The study shows a high incidence of cardiovascular complications in children with Kawasaki disease, indicating that coronary artery aneurysms and other heart complications are not just occasional.
  - reference: PMID:23075819
    reference_title: "Kawasaki disease: late cardiovascular sequelae."
    supports: REFUTE
    snippet: Patients with persistent or remodeled coronary aneurysms after Kawasaki disease have a high rate of complications including thrombosis or stenosis leading to myocardial infarction.
    explanation: The literature indicates a high rate of complications from coronary artery aneurysms in Kawasaki disease, suggesting that these complications are not occasional but rather significant.
- category: Hematologic
  name: Thrombocytosis
  description: Elevated platelet count commonly found in the subacute phase of Kawasaki disease.
  frequency: VERY_FREQUENT
  notes: Often appears 1-2 weeks after onset
  evidence:
  - reference: PMID:33527178
    reference_title: "Clinical implications of thrombocytosis in acute phase Kawasaki disease."
    supports: SUPPORT
    snippet: In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute phase.
    explanation: Thrombocytosis is a common finding during the subacute phase of KD.
  - reference: PMID:6833960
    reference_title: "Kawasaki disease."
    supports: SUPPORT
    snippet: The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash, joint manifestations, thrombocytosis, and cardiac disease.
    explanation: Thrombocytosis occurs during the subacute phase of KD.
  - reference: ORPHA:2331
    supports: PARTIAL
    snippet: "HP:0001894 | Thrombocytosis | Frequent (79-30%)"
    explanation: Orphanet classifies thrombocytosis as frequent (79-30%), while
      clinical consensus and this entry classify it as very frequent.
      Thrombocytosis is near-universal in the subacute phase.
  phenotype_term:
    preferred_term: Thrombocytosis
    description: Abnormally increased platelet count in the blood.
    term:
      id: HP:0001894
      label: Thrombocytosis
- category: Lymphatic
  name: Cervical Lymphadenopathy
  description: Enlarged cervical lymph nodes, often unilateral, one of the
    classic diagnostic criteria for Kawasaki disease. The least common of the
    five principal diagnostic features, reported in approximately 50-75% of
    cases.
  frequency: FREQUENT
  notes: Often unilateral presentation
  evidence:
  - reference: ORPHA:2331
    supports: PARTIAL
    snippet: "HP:0025289 | Cervical lymphadenopathy | Very frequent (99-80%)"
    explanation: Orphanet classifies cervical lymphadenopathy as very frequent
      (99-80%), but clinical series report it in 50-75% of cases, making it the
      least common of the five classic criteria. FREQUENT is retained based on
      published cohort data.
  - reference: PMID:26631821
    supports: SUPPORT
    snippet: The main symptoms were fever (100%), exanthema (98%), changes in
      the extremities (91%), conjunctivitis (77%), oral cavity changes (89%),
      cervical adenitis (55%) and cardiac abnormalities (45%).
    explanation: Cervical adenitis was present in 55% of adult KD cases in this
      French cohort.
  phenotype_term:
    preferred_term: Cervical lymphadenopathy
    description: Enlargement of lymph nodes in the neck region.
    term:
      id: HP:0025289
      label: Cervical lymphadenopathy
- category: Cardiovascular
  name: Myocarditis
  description: Inflammation of the myocardium that can occur during the acute phase of Kawasaki disease.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0012819 | Myocarditis | Occasional (29-5%)"
    explanation: Orphanet classifies myocarditis as occasional in Kawasaki disease.
  - reference: PMID:9665974
    supports: SUPPORT
    snippet: Common cardiovascular manifestations of the illness include myocarditis,
      pericardial effusion, and coronary artery aneurysm formation.
    explanation: Rowley and Shulman list myocarditis among common cardiovascular
      manifestations of Kawasaki syndrome.
  phenotype_term:
    preferred_term: Myocarditis
    description: Inflammation of the cardiac muscle.
    term:
      id: HP:0012819
      label: Myocarditis
- category: Cardiovascular
  name: Aneurysm Formation
  description: Vascular dilation resulting from inflammatory weakening of vessel walls, affecting coronary and other medium-sized arteries.
  frequency: FREQUENT
  evidence:
  - reference: PMID:31599798
    reference_title: "One year in review: Kawasaki disease."
    supports: SUPPORT
    snippet: Kawasaki disease is a childhood vasculitis of unknown origin, whose major complication is the development of coronary artery aneurysms (CAA).
    explanation: This reference directly states that coronary artery aneurysm development is a major complication of Kawasaki disease.
  - reference: PMID:21447126
    reference_title: "Pathogenesis of Kawasaki disease."
    supports: SUPPORT
    snippet: Histologically, coronary arteritis begins 6-8 days after the onset of KD, and leads immediately to inflammation of all layers of the artery. The inflammation spreads completely around the artery; as a result, structural components of the artery undergo intense damage; the artery then begins to dilate.
    explanation: This reference describes the mechanism by which arterial inflammation leads to dilation and aneurysm formation in Kawasaki disease.
  phenotype_term:
    preferred_term: Aneurysm Formation
    description: Abnormal focal dilation of a blood vessel due to weakening of the vessel wall.
    term:
      id: HP:0002617
      label: Vascular dilatation
- category: Cardiovascular
  name: Pericarditis
  description: Inflammation of the pericardium occurring during the acute phase
    of Kawasaki disease, sometimes with pericardial effusion.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0001701 | Pericarditis | Frequent (79-30%)"
    explanation: Orphanet classifies pericarditis as frequent in Kawasaki disease.
  - reference: PMID:9665974
    supports: PARTIAL
    snippet: Common cardiovascular manifestations of the illness include myocarditis,
      pericardial effusion, and coronary artery aneurysm formation.
    explanation: The snippet mentions pericardial effusion rather than
      pericarditis per se; pericardial effusion is a frequent accompaniment of
      pericarditis but they are distinct entities.
  phenotype_term:
    preferred_term: Pericarditis
    term:
      id: HP:0001701
      label: Pericarditis
- category: Cardiovascular
  name: Arrhythmia
  description: Cardiac rhythm disturbances that may occur during the acute or
    subacute phase of Kawasaki disease.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0011675 | Arrhythmia | Occasional (29-5%)"
    explanation: Orphanet classifies arrhythmia as occasional in Kawasaki disease.
  phenotype_term:
    preferred_term: Arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia
- category: Cardiovascular
  name: Abnormal Heart Valve Morphology
  description: Valvular abnormalities including mitral regurgitation that may
    occur in the acute phase of Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0001654 | Abnormal heart valve morphology | Frequent (79-30%)"
    explanation: Orphanet classifies abnormal heart valve morphology as frequent
      in Kawasaki disease.
  phenotype_term:
    preferred_term: Abnormal heart valve morphology
    term:
      id: HP:0001654
      label: Abnormal heart valve morphology
- category: Cardiovascular
  name: Congestive Heart Failure
  description: Heart failure that may occur in severe cases of Kawasaki disease,
    particularly with significant myocarditis or coronary artery involvement.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0001635 | Congestive heart failure | Occasional (29-5%)"
    explanation: Orphanet classifies congestive heart failure as occasional in
      Kawasaki disease.
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
- category: Dermatologic
  name: Palmoplantar Erythema
  description: Erythema of the palms and soles, a hallmark feature of the acute
    phase of Kawasaki disease.
  frequency: VERY_FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0025493 | Palmoplantar erythema | Very frequent (99-80%)"
    explanation: Orphanet classifies palmoplantar erythema as very frequent in
      Kawasaki disease.
  phenotype_term:
    preferred_term: Palmoplantar erythema
    term:
      id: HP:0025493
      label: Palmoplantar erythema
- category: Oropharyngeal
  name: Cheilitis
  description: Erythema, dryness, and fissuring of the lips, one of the classic
    mucocutaneous diagnostic criteria for Kawasaki disease.
  frequency: VERY_FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0100825 | Cheilitis | Very frequent (99-80%)"
    explanation: Orphanet classifies cheilitis as very frequent in Kawasaki disease.
  - reference: PMID:1440951
    supports: SUPPORT
    snippet: We describe a four-year-old girl who presented with fever, a
      diffuse erythematous maculopapular rash, bilateral nonpurulent bulbar
      conjunctivitis, dry, red, fissured lips, a tongue with a strawberry
      'appearance', an erythematous pharynx, indurative erythema, and edema and
      desquamation of the face, hands and feet.
    explanation: Dry, red, fissured lips are described as a presenting feature
      of Kawasaki syndrome.
  - reference: PMID:26631821
    supports: SUPPORT
    snippet: The main symptoms were fever (100%), exanthema (98%), changes in
      the extremities (91%), conjunctivitis (77%), oral cavity changes (89%),
      cervical adenitis (55%) and cardiac abnormalities (45%).
    explanation: Oral cavity changes (including lip involvement) were present in
      89% of cases, supporting very frequent classification.
  phenotype_term:
    preferred_term: Cheilitis
    term:
      id: HP:0100825
      label: Cheilitis
- category: Oropharyngeal
  name: Strawberry Tongue
  description: Erythematous tongue with prominent papillae, a characteristic
    oral finding in Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0031042 | Strawberry tongue | Frequent (79-30%)"
    explanation: Orphanet classifies strawberry tongue as frequent in Kawasaki disease.
  - reference: PMID:15835487
    supports: SUPPORT
    snippet: The disease can present with protean clinical manifestations which
      include high grade fever (for at least 5 days), rash, redness of the lips
      and a typical strawberry tongue, cervical lymph node enlargement (often
      unilateral), swelling over the hands/feet and, later a characteristic
      peripheral desquamation over the fingers and toes.
    explanation: Strawberry tongue is listed as a typical clinical manifestation
      of Kawasaki disease.
  phenotype_term:
    preferred_term: Strawberry tongue
    term:
      id: HP:0031042
      label: Strawberry tongue
- category: Oropharyngeal
  name: Pharyngitis
  description: Erythema and inflammation of the pharynx, part of the diffuse
    oropharyngeal involvement in the acute phase of Kawasaki disease.
  frequency: VERY_FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: PARTIAL
    snippet: "HP:0100776 | Recurrent pharyngitis | Very frequent (99-80%)"
    explanation: Orphanet lists recurrent pharyngitis (HP:0100776) as very
      frequent, but KD pharyngitis is acute, not recurrent. HP:0025439
      (Pharyngitis) is used here as the more accurate term. The frequency
      data supports pharyngeal involvement being very frequent.
  phenotype_term:
    preferred_term: Pharyngitis
    term:
      id: HP:0025439
      label: Pharyngitis
- category: Oropharyngeal
  name: Glossitis
  description: Inflammation of the tongue contributing to the characteristic oral
    mucosal changes in Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0000206 | Glossitis | Frequent (79-30%)"
    explanation: Orphanet classifies glossitis as frequent in Kawasaki disease.
  phenotype_term:
    preferred_term: Glossitis
    term:
      id: HP:0000206
      label: Glossitis
- category: Dermatologic
  name: Scaling Skin on Fingertip
  description: Desquamation beginning at the tips of fingers and toes, spreading
    to palms and soles during the subacute recovery phase. A hallmark late
    finding in Kawasaki disease.
  frequency: FREQUENT
  notes: Particularly on the fingers and toes, often during the subacute phase
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0025525 | Scaling skin on fingertip | Frequent (79-30%)"
    explanation: Orphanet classifies fingertip scaling as frequent in Kawasaki disease.
  - reference: PMID:3333141
    supports: SUPPORT
    snippet: Peeling of skin of fingers and toes, arthralgia, and marked
      thrombocytosis are frequent 1-2 weeks after onset.
    explanation: Peeling of fingers is described as frequent 1-2 weeks after
      onset of Kawasaki disease.
  - reference: PMID:6833960
    supports: SUPPORT
    snippet: The second, subacute, phase begins with a decline of the acute
      findings and proceeds with desquamation of rash...
    explanation: Desquamation is a frequent dermatologic manifestation during
      the subacute phase of Kawasaki disease.
  - reference: PMID:37065507
    supports: SUPPORT
    snippet: Kawasaki disease's clinical manifestations range from oral skin
      disease to the blistering of the mucosa, symptoms involving the hands and
      the feet, skin disease of the palms and soles, a desquamative rash...
    explanation: Desquamative rash involving hands, feet, palms, and soles is
      described as a clinical manifestation of Kawasaki disease.
  phenotype_term:
    preferred_term: Scaling skin on fingertip
    term:
      id: HP:0025525
      label: Scaling skin on fingertip
- category: Dermatologic
  name: Abnormality of Nail Color
  description: Nail changes including Beau's lines and discoloration observed
    during convalescence of Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0100643 | Abnormality of nail color | Frequent (79-30%)"
    explanation: Orphanet classifies nail color abnormalities as frequent in
      Kawasaki disease.
  phenotype_term:
    preferred_term: Abnormality of nail color
    term:
      id: HP:0100643
      label: Abnormality of nail color
- category: Musculoskeletal
  name: Palmar Edema
  description: Swelling of the palms with induration, a distinctive finding in
    the acute phase of Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0025538 | Palmar edema | Frequent (79-30%)"
    explanation: Orphanet classifies palmar edema as frequent in Kawasaki disease.
  phenotype_term:
    preferred_term: Palmar edema
    term:
      id: HP:0025538
      label: Palmar edema
- category: Musculoskeletal
  name: Plantar Edema
  description: Swelling of the soles with induration, accompanying palmar edema
    in the acute phase of Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0025537 | Plantar edema | Frequent (79-30%)"
    explanation: Orphanet classifies plantar edema as frequent in Kawasaki disease.
  phenotype_term:
    preferred_term: Plantar edema
    term:
      id: HP:0025537
      label: Plantar edema
- category: Gastrointestinal
  name: Diarrhea
  description: Gastrointestinal involvement with diarrhea is a common
    extracardiac manifestation of Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0002014 | Diarrhea | Frequent (79-30%)"
    explanation: Orphanet classifies diarrhea as frequent in Kawasaki disease.
  - reference: PMID:30029859
    supports: PARTIAL
    snippet: Fever, abdominal pain, and vomiting were the most frequent symptoms
      observed and typical Kawasaki disease signs and symptoms appeared after
      intestinal complaints in all cases.
    explanation: The snippet documents GI involvement in KD but mentions
      abdominal pain and vomiting rather than diarrhea specifically.
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
    temporality: ACUTE
- category: Gastrointestinal
  name: Abdominal Pain
  description: Abdominal pain occurring in Kawasaki disease, sometimes preceding
    the classic diagnostic features and leading to diagnostic confusion.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0002027 | Abdominal pain | Frequent (79-30%)"
    explanation: Orphanet classifies abdominal pain as frequent in Kawasaki disease.
  - reference: PMID:30029859
    supports: SUPPORT
    snippet: Fever, abdominal pain, and vomiting were the most frequent symptoms
      observed and typical Kawasaki disease signs and symptoms appeared after
      intestinal complaints in all cases.
    explanation: Abdominal pain is one of the most frequent gastrointestinal
      symptoms in Kawasaki disease.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
- category: Gastrointestinal
  name: Nausea and Vomiting
  description: Nausea and vomiting occurring as part of gastrointestinal
    involvement in Kawasaki disease.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0002017 | Nausea and vomiting | Occasional (29-5%)"
    explanation: Orphanet classifies nausea and vomiting as occasional in Kawasaki
      disease.
  phenotype_term:
    preferred_term: Nausea and vomiting
    term:
      id: HP:0002017
      label: Nausea and vomiting
- category: Hepatic
  name: Hepatitis
  description: Hepatic inflammation manifesting as elevated transaminases,
    occurring as an extracardiac complication of Kawasaki disease.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0012115 | Hepatitis | Occasional (29-5%)"
    explanation: Orphanet classifies hepatitis as occasional in Kawasaki disease.
  - reference: PMID:36557034
    supports: SUPPORT
    snippet: Out of these six KD patients, there were
      two patients complicated with hepatitis and one patient with gallbladder
      hydrops. Different clinical features including jaundice (n = 3) and hepatomegaly
      (n = 4) were also observed.
    explanation: Case series confirms hepatitis and hepatomegaly as hepatobiliary
      complications of Kawasaki disease.
  phenotype_term:
    preferred_term: Hepatitis
    term:
      id: HP:0012115
      label: Hepatitis
- category: Hepatic
  name: Jaundice
  description: Yellowing of the skin and sclera due to hepatobiliary involvement
    in Kawasaki disease.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0000952 | Jaundice | Occasional (29-5%)"
    explanation: Orphanet classifies jaundice as occasional in Kawasaki disease.
  - reference: PMID:36557034
    supports: SUPPORT
    snippet: Different clinical features including jaundice (n = 3) and hepatomegaly
      (n = 4) were also observed.
    explanation: Jaundice was observed in KD patients with hepatobiliary
      manifestations.
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
- category: Hepatic
  name: Cholecystitis
  description: Gallbladder inflammation including hydrops that may complicate
    Kawasaki disease.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0001082 | Cholecystitis | Occasional (29-5%)"
    explanation: Orphanet classifies cholecystitis as occasional in Kawasaki disease.
  phenotype_term:
    preferred_term: Cholecystitis
    term:
      id: HP:0001082
      label: Cholecystitis
- category: Renal
  name: Proteinuria
  description: Protein in the urine reflecting renal involvement in the systemic
    vasculitis of Kawasaki disease.
  frequency: VERY_FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0000093 | Proteinuria | Very frequent (99-80%)"
    explanation: Orphanet classifies proteinuria as very frequent in Kawasaki disease.
  - reference: PMID:27287282
    supports: SUPPORT
    snippet: Genitourinary
      involvement in patients with Kawasaki disease is typically limited to sterile
      pyuria and proteinuria.
    explanation: Proteinuria is described as a typical genitourinary finding in
      Kawasaki disease.
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: Proteinuria
- category: Renal
  name: Sterile Pyuria
  description: White blood cells in the urine without bacterial infection,
    reflecting urinary tract inflammation in Kawasaki disease.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0100586 | Sterile pyuria | Occasional (29-5%)"
    explanation: Orphanet classifies sterile pyuria as occasional in Kawasaki disease.
  - reference: PMID:23390440
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a systemic vasculitis and affects many organ
      systems. It often presents sterile pyuria, microscopic hematuria, and
      proteinuria due to renal involvement.
    explanation: Sterile pyuria is a recognized renal manifestation of Kawasaki
      disease.
  phenotype_term:
    preferred_term: Sterile pyuria
    term:
      id: HP:0100586
      label: Sterile pyuria
- category: Musculoskeletal
  name: Arthritis
  description: Non-erosive, self-limiting arthritis affecting predominantly the
    knees, ankles, and hips, occurring in 2-31% of children with Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0001369 | Arthritis | Frequent (79-30%)"
    explanation: Orphanet classifies arthritis as frequent in Kawasaki disease.
  - reference: PMID:31974671
    supports: PARTIAL
    snippet: Eight hundred sixty-five children (male:female 29:11) were diagnosed with
      KD during this period-of these, 40 (4.6%) had arthritis.
    explanation: This cohort shows 4.6% incidence (OCCASIONAL range), while
      ORPHA classifies arthritis as frequent. The wide reported range (2-31%)
      across studies suggests variability in ascertainment.
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
- category: Musculoskeletal
  name: Arthralgia
  description: Joint pain without frank arthritis, a common musculoskeletal
    complaint in Kawasaki disease, particularly during the subacute phase.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0002829 | Arthralgia | Occasional (29-5%)"
    explanation: Orphanet classifies arthralgia as occasional in Kawasaki disease.
  - reference: PMID:3333141
    supports: PARTIAL
    snippet: Peeling of skin of fingers and toes, arthralgia, and marked
      thrombocytosis are frequent 1-2 weeks after onset.
    explanation: Arthralgia is described as frequent in this reference, while
      ORPHA classifies it as occasional (29-5%). The discrepancy may reflect
      differences in ascertainment criteria.
  phenotype_term:
    preferred_term: Arthralgia
    term:
      id: HP:0002829
      label: Arthralgia
- category: Hematologic
  name: Leukocytosis
  description: Elevated white blood cell count with neutrophilic predominance,
    reflecting the systemic inflammatory response in Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0001974 | Leukocytosis | Frequent (79-30%)"
    explanation: Orphanet classifies leukocytosis as frequent in Kawasaki disease.
  phenotype_term:
    preferred_term: Leukocytosis
    term:
      id: HP:0001974
      label: Increased total leukocyte count
- category: Systemic
  name: Vasculitis
  description: Systemic medium-vessel vasculitis, the defining feature of
    Kawasaki disease affecting coronary and other medium-sized arteries.
  frequency: VERY_FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0002633 | Vasculitis | Very frequent (99-80%)"
    explanation: Orphanet classifies vasculitis as very frequent in Kawasaki
      disease, consistent with vasculitis being the defining pathological feature.
  phenotype_term:
    preferred_term: Vasculitis
    term:
      id: HP:0002633
      label: Vasculitis
- category: Systemic
  name: Fatigue
  description: Generalized fatigue and malaise accompanying the systemic
    inflammatory response in Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0012378 | Fatigue | Frequent (79-30%)"
    explanation: Orphanet classifies fatigue as frequent in Kawasaki disease.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Systemic
  name: Edema
  description: Peripheral edema of the extremities occurring during the acute
    phase of Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0000969 | Edema | Frequent (79-30%)"
    explanation: Orphanet classifies edema as frequent in Kawasaki disease.
  phenotype_term:
    preferred_term: Edema
    term:
      id: HP:0000969
      label: Edema
- category: Neurological
  name: Irritability
  description: Extreme irritability in affected children, a notable neurological
    feature that may precede or accompany the acute febrile phase.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0000737 | Irritability | Occasional (29-5%)"
    explanation: Orphanet classifies irritability as occasional in Kawasaki disease.
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
- category: Neurological
  name: Aseptic Meningitis
  description: Cerebrospinal fluid pleocytosis without bacterial infection,
    occurring as a neurological complication of Kawasaki disease.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0001287 | Meningitis | Occasional (29-5%)"
    explanation: Orphanet classifies meningitis as occasional in Kawasaki disease.
  - reference: PMID:33530798
    supports: SUPPORT
    snippet: Aseptic meningitis (AM) is an uncommon feature of KD.
    explanation: Full-text directly characterizes aseptic meningitis as an
      uncommon but recognized feature of Kawasaki disease.
  phenotype_term:
    preferred_term: Aseptic meningitis
    term:
      id: HP:0001287
      label: Meningitis
- category: Neurological
  name: Cranial Nerve Paralysis
  description: Rare neurological complication of Kawasaki disease, most commonly
    affecting the facial nerve (VII), associated with more severe disease
    and coronary artery involvement.
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0006824 | Cranial nerve paralysis | Occasional (29-5%)"
    explanation: Orphanet classifies cranial nerve paralysis as occasional in
      Kawasaki disease.
  - reference: PMID:31364426
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is an acute multisystem vasculitic syndrome
      that predominantly affects infants and young children. Neurological
      complications are rare in patients with KD and the diagnosis is challenging.
    explanation: Case report with literature review documents bilateral facial
      nerve palsy and meningitis as rare neurological complications of KD.
  phenotype_term:
    preferred_term: Cranial nerve paralysis
    term:
      id: HP:0006824
      label: Cranial nerve paralysis
- category: Hematologic
  name: Hypoalbuminemia
  description: Decreased serum albumin levels reflecting systemic inflammation
    and capillary leak in Kawasaki disease.
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:2331
    supports: SUPPORT
    snippet: "HP:0003073 | Hypoalbuminemia | Frequent (79-30%)"
    explanation: Orphanet classifies hypoalbuminemia as frequent in Kawasaki disease.
  phenotype_term:
    preferred_term: Hypoalbuminemia
    term:
      id: HP:0003073
      label: Hypoalbuminemia
biochemical:
- name: C-Reactive Protein (CRP)
  presence: Elevated
  context: Indicator of inflammation
  evidence:
  - reference: PMID:34078404
    reference_title: "The occurrence of coronary artery lesions in Kawasaki disease based on C-reactive protein levels: a retrospective cohort study."
    supports: SUPPORT
    snippet: CAL were found in 12.9 and 18.3% of the high and low CRP patients, respectively (p < 0.001), based on z-scores; and in 9.9 and 12.5%, respectively (p = 0.001), based on the Japanese criteria in the acute phase.
    explanation: The study indicates that CRP levels are elevated in Kawasaki Disease patients, with specific percentages of high and low CRP levels noted.
  - reference: PMID:39117827
    reference_title: "Kawasaki Disease-Associated Cytokine Storm Syndrome."
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy.
    explanation: The abstract describes KD as a hyperinflammatory syndrome, implying elevated inflammatory markers such as CRP.
  - reference: PMID:37551875
    reference_title: "N-Terminal Pro-Brain Natriuretic Peptide Levels in Kawasaki Disease, Sepsis and Other Febrile Illnesses."
    supports: SUPPORT
    snippet: Complete blood count, C-reactive protein (CRP), liver and renal function tests, serum electrolytes, chest X-ray, NT-proBNP level, Bactec blood culture, urine microscopy and culture along with detailed physical examination was done for all cases and control.
    explanation: The study includes CRP as part of the diagnostic tests for Kawasaki Disease, indicating its relevance as an inflammatory marker.
  - reference: PMID:34731266
    reference_title: "Clinical indications for Kawasaki disease in febrile infants aged less than three months."
    supports: SUPPORT
    snippet: The KD group had a significantly higher level of initial c-reactive protein (CRP) compared to the BI and NBI groups, with a cutoff value of 4.85 mg/dL in comparison with the BI group and 3.32 mg/dL in comparison with the NBI group.
    explanation: The study provides specific CRP levels that are elevated in Kawasaki Disease compared to bacterial and non-bacterial infections.
- name: Erythrocyte Sedimentation Rate (ESR)
  presence: Elevated
  context: Indicator of inflammation
  evidence:
  - reference: PMID:36604937
    reference_title: "Neutrophil-Lymphocyte Ratio for Predicting Coronary Artery Lesions in Children With Kawasaki Disease."
    supports: SUPPORT
    snippet: NLR >/=2.08 was 82% sensitive and 80% specific in predicting CAL. ESR >/=88 mm/h was 85% sensitive and 64% specific in predicting IVIg resistance.
    explanation: The study indicates that ESR is elevated in Kawasaki Disease and can be used to predict IVIg resistance.
  - reference: PMID:33413220
    reference_title: "Clinical aspects for differential diagnosis of Kawasaki disease shock syndrome: a case control study."
    supports: SUPPORT
    snippet: In comparison between KDSS and TSS, patients with KDSS had a significantly higher erythrocyte sedimentation rate (ESR) and significantly lower creatinine.
    explanation: The study shows that patients with Kawasaki Disease Shock Syndrome (KDSS) have significantly higher ESR levels.
  - reference: PMID:15677370
    reference_title: "High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease."
    supports: SUPPORT
    snippet: The erythrocyte sedimentation rate (ESR) increased significantly 24 h after IVIG, and the elevated level was sustained for 7 days.
    explanation: This reference shows that ESR levels are elevated during the acute stage of Kawasaki Disease.
- name: Platelet Count
  presence: Elevated
  context: Often seen in the subacute phase
  evidence:
  - reference: PMID:33527178
    reference_title: "Clinical implications of thrombocytosis in acute phase Kawasaki disease."
    supports: SUPPORT
    snippet: In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute phase.
    explanation: The abstract states that thrombocytosis (elevated platelet count) is commonly found in the subacute phase of Kawasaki disease.
  - reference: PMID:6833960
    reference_title: "Kawasaki disease."
    supports: SUPPORT
    snippet: The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash, joint manifestations, thrombocytosis, and cardiac disease.
    explanation: The text explicitly mentions that thrombocytosis occurs during the subacute phase of Kawasaki disease.
diagnosis:
- name: Echocardiogram
  description: Cardiac ultrasound to detect coronary artery dilation, aneurysms, and other cardiac abnormalities.
  notes: Used to check for coronary artery involvement
  evidence:
  - reference: PMID:28921836
    reference_title: "Clinical assessment of coronary arteries in Kawasaki disease: Focus on echocardiographic assessment."
    supports: SUPPORT
    snippet: Echocardiography is an excellent noninvasive imaging modality for evaluation and follow-up of cardiac lesions, especially coronary artery changes occurring as a result of Kawasaki disease.
    explanation: The reference clearly states that echocardiography is used to evaluate coronary artery changes in Kawasaki disease, supporting the statement.
- name: Blood Tests
  description: Laboratory assessment including CRP, ESR, platelet count, and white blood cell count to evaluate inflammation.
  notes: Elevated inflammatory markers (CRP and ESR)
  evidence:
  - reference: PMID:36569014
    reference_title: "Kawasaki disease without changes in inflammatory biomarkers: A case report."
    supports: PARTIAL
    snippet: Since KD is a disease caused by arterial inflammation, many patients with KD have elevated levels of inflammatory biomarkers, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and serum amyloid A protein (SAA) in blood tests.
    explanation: The literature suggests that many patients with Kawasaki Disease have elevated inflammatory markers, but it also reports cases where such elevations are not observed.
  - reference: PMID:34854940
    reference_title: "Assessing the Association of Kawasaki Disease Symptoms and Echocardiographic Findings."
    supports: SUPPORT
    snippet: Thrombocytosis, conjunctivitis, and oral and/or pharyngeal erythema and/or strawberry tongue were associated with higher rates of echocardiographic abnormalities.
    explanation: The study indicates that inflammatory markers are associated with echocardiographic abnormalities in Kawasaki Disease, supporting the statement.
  - reference: PMID:33481812
    reference_title: "A novel score system of blood tests for differentiating Kawasaki disease from febrile children."
    supports: SUPPORT
    snippet: We obtained eight independent predictors (platelets, eosinophil, alanine aminotransferase, C-reactive protein, hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and monocyte).
    explanation: CRP is identified as one of the independent predictors for Kawasaki Disease, supporting the statement.
  - reference: PMID:27881022
    reference_title: "Elevated serum YKL-40 levels in patients with Kawasaki disease."
    supports: SUPPORT
    snippet: YKL-40 concentration in the serum of KD patients significantly increased during the acute disease phase compared with those of disease controls and healthy controls.
    explanation: The study supports the presence of elevated inflammatory markers in Kawasaki Disease patients.
  - reference: PMID:37188888
    reference_title: "Prokineticin 2 as a potential biomarker for the diagnosis of Kawasaki disease."
    supports: SUPPORT
    snippet: PK2 can significantly predict Kawasaki disease independently of CRP and ESR (p < 0.0001).
    explanation: CRP and ESR are mentioned as markers that can independently predict Kawasaki Disease, supporting the statement.
genetic:
- name: ITPKC
  association: Risk variant reduces negative regulation of Ca2+/NFAT signaling leading to enhanced T-cell activation
  notes: Associated with coronary lesions and hyperinflammation; rationale for calcineurin inhibitors
- name: FCGR2A
  association: Mediates immune-complex driven neutrophil/monocyte activation
  notes: Mechanistic basis for IVIG competing at FcγRs; genetic association with susceptibility
- name: FCGR3A
  association: Mediates immune-complex driven neutrophil/monocyte activation
  notes: Involved in FcγR signaling and immune complex handling
- name: BLK
  association: B lymphoid tyrosine kinase involved in B-cell receptor signaling
  notes: Genetic locus implicated in altered B-cell/plasmablast responses
- name: CD40
  association: Promotes B/T cell and endothelial activation via CD40-CD40L co-stimulation
  notes: CD40L on T cells linked to endothelial cell activation and inflammation
- name: HLA-B
  association: HLA associations support antigen-driven or superantigen-like T-cell responses
  notes: Shapes disease susceptibility; useful for dissecting trigger(s) and host response subtypes
- name: CASP3
  association: Implicated in endothelial cell apoptosis and vascular remodeling during acute vasculitis
  notes: Apoptosis modulation is investigational
- name: ORAI1
  association: Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling
  notes: Heightened T-cell responses contribute to hyperinflammation
- name: STIM1
  association: Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling
  notes: Points to SOCE or calcineurin/NFAT modulation as therapeutic option
- name: TGFBR2
  association: TGF-β receptor involved in endothelial-to-mesenchymal transition
  notes: Drives EndMT and luminal myofibroblast proliferation leading to stenosis/aneurysm formation
- name: SMAD3
  association: TGF-β signaling mediator involved in vascular remodeling
  notes: Anti-fibrotic or TGF-β pathway modulation is theoretical target
- name: TGFB2
  association: TGF-β signaling involved in chronic vascular remodeling
  notes: Informs long-term vascular remodeling targets
- name: IL1B
  association: IL-1β promotes endothelial injury, inflammation and remodeling
  notes: Direct IL-1 blockade (anakinra) has mechanistic and clinical rationale for IVIG-resistant KD
- name: IL1R1
  association: IL-1 receptor; downstream of inflammasome activation
  notes: IL-1 pathway is therapeutic target
- name: TNF
  association: Induces endothelial cell expression of ICAM-1/VCAM-1, iNOS and proinflammatory cascade
  notes: Anti-TNF therapy (infliximab) used for IVIG-resistant cases
- name: IL17A
  association: Th17 expansion and elevated IL-17 associate with coronary damage and IVIG resistance
  notes: Promotes neutrophil recruitment; IL-17/IL-23 pathway inhibitors are investigational
- name: IL23A
  association: IL-23 involved in Th17 axis and IL-17 signaling
  notes: Potential investigational approach in select patients
- name: NLRP3
  association: NLRP3 inflammasome activation leads to IL-1β release and pyroptosis
  notes: NLRP3 or IL-1 pathway inhibition offers mechanistic target
- name: NOS3
  association: Reduced eNOS expression/activity leads to decreased NO, vasoconstriction, and thrombosis
  notes: Supports vascular-protective strategies and monitoring of endothelial function
- name: ICAM1
  association: Upregulated by TNF/IL-1 leading to leukocyte recruitment and endothelial dysfunction
  notes: Adhesion-inflammation axis is biomarker and potential target
- name: VCAM1
  association: Upregulated by TNF/IL-1 leading to vascular injury
  notes: Part of adhesion-inflammation axis
treatments:
- name: Intravenous Immunoglobulin (IVIG)
  description: First-line treatment to reduce inflammation and risk of coronary artery complications.
  evidence:
  - reference: PMID:23283289
    reference_title: "Advances in the treatment of Kawasaki disease."
    supports: SUPPORT
    snippet: Intravenous immunoglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease.
    explanation: The literature confirms that IVIG is part of the standard initial therapy for Kawasaki disease, aimed at reducing inflammation and preventing coronary artery complications.
  - reference: PMID:38135926
    reference_title: "Early Clinical Evaluation of Coronary Artery Lesions in Kawasaki Disease."
    supports: SUPPORT
    snippet: For KD patients, male, children aged 3 to 9 years, and those with fever longer than 6 days before intravenous immunoglobulin (IVIG) use were more likely to have CAL.
    explanation: The study discusses the use of IVIG and its timing in relation to the risk of coronary artery lesions, supporting its role in reducing such risks.
  - reference: PMID:24034380
    reference_title: "Kawasaki disease: part II. Complications and treatment."
    supports: SUPPORT
    snippet: The standard of care for treatment is intravenous immunoglobulin plus aspirin, but adding corticosteroids may provide additional benefit for high-risk patients.
    explanation: The literature states that IVIG is the standard of care for treating Kawasaki disease to reduce coronary artery complications.
  - reference: PMID:34535199
    reference_title: "Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease."
    supports: SUPPORT
    snippet: Intravenous immunoglobulin (IVIG) has become an effective treatment regimen, which can effectively reduce the incidence of cardiovascular complications.
    explanation: The literature confirms that IVIG is effective in reducing cardiovascular complications in Kawasaki disease.
  - reference: PMID:32888683
    reference_title: "Update on the Management of Kawasaki Disease."
    supports: SUPPORT
    snippet: Treatment of Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) administered within the initial 10 days of fever onset decreases the risk of coronary artery aneurysms (CAAs) from ∼ 25% to less than 5%.
    explanation: The literature provides evidence that IVIG significantly reduces the risk of coronary artery complications when administered early.
  treatment_term:
    preferred_term: intravenous immunoglobulin therapy
    description: Treatment of disease through the administration of medications.
    term:
      id: MAXO:0001480
      label: immunoglobulin infusion therapy
- name: Aspirin
  description: Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots.
  evidence:
  - reference: PMID:9513217
    reference_title: "Kawasaki disease: a dangerous acute childhood illness."
    supports: SUPPORT
    snippet: Treatment includes the hospitalization of the child and subsequent administration of high doses of aspirin and intravenous immunoglobulin. With recovery, aspirin doses are reduced and the child may be monitored at home with outpatient follow-up.
    explanation: This reference confirms that high doses of aspirin are used initially for Kawasaki disease, followed by lower doses after recovery.
  - reference: PMID:10935427
    reference_title: "New perspectives in the drug treatment of Kawasaki disease."
    supports: SUPPORT
    snippet: Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose until the fourteenth day of illness then low dose).
    explanation: This reference also supports the statement that high doses of aspirin are used initially, followed by lower doses.
  - reference: PMID:32159800
    reference_title: "What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis."
    supports: PARTIAL
    snippet: Low-dose aspirin plus IVIG might be as effective as high-dose aspirin plus IVIG for the initial treatment of Kawasaki disease. Considering that high-dose aspirin may cause more adverse reactions than low-dose aspirin, low-dose aspirin plus IVIG should be recommended as the first-line therapy in the initial treatment of Kawasaki disease.
    explanation: This reference suggests that low-dose aspirin might be equally effective as high-dose aspirin and should be recommended to avoid adverse reactions, indicating a shift in treatment preference.
  - reference: PMID:28043685
    reference_title: "Medium- or Higher-Dose Acetylsalicylic Acid for Acute Kawasaki Disease and Patient Outcomes."
    supports: PARTIAL
    snippet: The use of medium- or higher-dose ASA in acute Kawasaki disease did not prevent CAA. A future randomized controlled trial is needed to determine the optimum dose of ASA.
    explanation: This reference indicates that higher doses of aspirin did not prevent coronary artery aneurysms and suggests the need for further research to determine the optimal dose.
  treatment_term:
    preferred_term: cardiovascular agent therapy
    description: Treatment using medications that affect the cardiovascular system, including antiplatelet agents.
    term:
      id: MAXO:0000181
      label: cardiovascular agent therapy
- name: Anakinra
  description: IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury.
  notes: Mechanistic rationale based on NLRP3 inflammasome and IL-1β pathway activation
  treatment_term:
    preferred_term: Pharmacotherapy
    description: Treatment using IL-1 pathway inhibition for refractory inflammation.
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: anakinra
      term:
        id: NCIT:C38717
        label: Anakinra
- name: Cyclosporine
  description: Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients.
  notes: Targets dysregulated calcium signaling pathway; used for IVIG-resistant cases
  treatment_term:
    preferred_term: Pharmacotherapy
    description: Treatment using calcineurin inhibition to reduce T-cell activation.
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cyclosporine
      term:
        id: NCIT:C406
        label: Cyclosporine
- name: Corticosteroids
  description: Used in cases resistant to IVIG or with severe inflammation.
  evidence:
  - reference: PMID:31914832
    reference_title: "The role of corticosteroids in the treatment of Kawasaki disease."
    supports: SUPPORT
    snippet: We suggest using methylprednisolone pulse therapy as an alternative rescue therapy for immunoglobulin-resistant KD, as well as identifying high-risk patients who need initial corticosteroid with IVIG treatment with an adequate route, dose, and duration.
    explanation: The literature supports the use of corticosteroids in cases of Kawasaki Disease that are resistant to IVIG or in high-risk patients with severe inflammation.
  - reference: PMID:29101553
    reference_title: "Treatment Options for Resistant Kawasaki Disease."
    supports: SUPPORT
    snippet: '"Resistant" Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some treatments is considerable.'
    explanation: This reference discusses the management of resistant Kawasaki Disease, which includes considering corticosteroid use.
  - reference: PMID:33541111
    reference_title: "Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE."
    supports: SUPPORT
    snippet: To prevent CAA, more intensified or adjunctive therapies using other agents, such as pulsed methylprednisolone, ciclosporin, infliximab, and Anakinra, should be considered for patients with these risk factors.
    explanation: This reference mentions the use of pulsed methylprednisolone (a corticosteroid) for patients with Kawasaki Disease who are at risk of developing coronary artery abnormalities, indicating severe inflammation.
  treatment_term:
    preferred_term: systemic corticosteroid therapy
    description: Treatment using corticosteroids to reduce inflammation in refractory cases.
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
- name: Infliximab
  description: Anti-TNF monoclonal antibody used for IVIG-resistant Kawasaki
    disease to block TNF-mediated endothelial activation and inflammation.
  notes: Second-line treatment for refractory KD; targets TNF-driven
    inflammation
  evidence:
  - reference: PMID:33541111
    supports: SUPPORT
    snippet: To prevent CAA, more
      intensified or adjunctive therapies using other agents, such as pulsed
      methylprednisolone, ciclosporin, infliximab, and Anakinra, should be considered
      for patients with these risk factors.
    explanation: Infliximab is listed among adjunctive therapies for IVIG-resistant
      KD patients at risk of coronary artery abnormalities.
  treatment_term:
    preferred_term: Pharmacotherapy
    description: Anti-TNF biologic therapy for refractory Kawasaki disease.
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: infliximab
      term:
        id: NCIT:C1789
        label: Infliximab
notes: Prompt treatment is crucial to prevent coronary artery complications.
  Long-term follow-up may be necessary for some patients.
disease_term:
  preferred_term: Kawasaki disease
  description: An acute febrile vasculitis of childhood primarily affecting medium-sized arteries with risk of coronary artery complications.
  term:
    id: MONDO:0012727
    label: Kawasaki disease
classifications:
  harrisons_chapter:
  - classification_value: CARDIOVASCULAR
  - classification_value: IMMUNE_RHEUMATOLOGIC
references:
- reference: DOI:10.1016/j.pedneo.2023.05.002
  title: Pathophysiological and clinical point of view on Kawasaki disease and MIS-C
  findings: []
- reference: DOI:10.1111/1756-185x.14816
  title: 'An update on understanding the <scp>pathophysiology</scp> in Kawasaki disease: Possible role of immune complexes in coronary artery lesion revisited'
  findings: []
- reference: DOI:10.1172/jci176938
  title: The etiologies of Kawasaki disease
  findings: []
- reference: DOI:10.3389/fimmu.2024.1323171
  title: FCGR2/3 polymorphisms are associated with susceptibility to Kawasaki disease but do not predict intravenous immunoglobulin resistance and coronary artery aneurysms
  findings: []
- reference: DOI:10.3389/fped.2024.1415941
  title: Research perspective in the clinical management of Kawasaki disease
  findings: []
- reference: DOI:10.3390/ijms252413322
  title: 'Endothelial Dysfunction: Molecular Mechanisms and Therapeutic Strategies in Kawasaki Disease'
  findings: []
- reference: DOI:10.52533/johs.2024.40109
  title: Etiology, Pathophysiology, Diagnosis and Management of Kawasaki Disease
  findings: []
📚

References & Deep Research

References

7
Pathophysiological and clinical point of view on Kawasaki disease and MIS-C
No top-level findings curated for this source.
An update on understanding the <scp>pathophysiology</scp> in Kawasaki disease: Possible role of immune complexes in coronary artery lesion revisited
No top-level findings curated for this source.
The etiologies of Kawasaki disease
No top-level findings curated for this source.
FCGR2/3 polymorphisms are associated with susceptibility to Kawasaki disease but do not predict intravenous immunoglobulin resistance and coronary artery aneurysms
No top-level findings curated for this source.
Research perspective in the clinical management of Kawasaki disease
No top-level findings curated for this source.
Endothelial Dysfunction: Molecular Mechanisms and Therapeutic Strategies in Kawasaki Disease
No top-level findings curated for this source.
Etiology, Pathophysiology, Diagnosis and Management of Kawasaki Disease
No top-level findings curated for this source.

Deep Research

2
Disorder

Disorder

  • Name: Kawasaki Disease
  • Category: Pediatric Condition
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 88

Key Pathophysiology Nodes

  • Vascular Inflammation
  • Immune Response Dysregulation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.pedneo.2023.05.002
  • DOI:10.1111/1756-185x.14816
  • DOI:10.1172/jci176938
  • DOI:10.3389/fimmu.2024.1323171
  • DOI:10.3389/fped.2024.1415941
  • DOI:10.3390/ijms252413322
  • DOI:10.52533/johs.2024.40109
Falcon
Pathophysiology description (current understanding)
Edison Scientific Literature 21 citations 2025-12-15T09:34:12.783296

Pathophysiology description (current understanding)

Kawasaki disease is an acute, self-limited, systemic vasculitis of medium-sized arteries with a predilection for the coronary arteries, driven by a genetically primed, dysregulated innate and adaptive immune response to one or more infectious/environmental triggers that culminates in endothelial activation/dysfunction and layered coronary-artery wall inflammation and remodeling (necrotizing arteritis, subacute/chronic vasculitis, luminal myofibroblast proliferation) (burns2024theetiologiesof pages 4-5, paolini2024endothelialdysfunctionmolecular pages 2-4, paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6). Recent reviews emphasize heterogeneous etiologies with epidemiologic signals for a respiratory-transmitted trigger and convergent, antigen-driven plasmablast responses in some patients, while genetic susceptibility (e.g., ITPKC, FCGR, HLA, CD40, BLK; Ca2+/NFAT, FcγR, and TGF-β pathway variants) shapes endotypes and clinical risk (burns2024theetiologiesof pages 4-5, paolini2024endothelialdysfunctionmolecular pages 2-4, vankova2023pathophysiologicalandclinical pages 13-17). Endothelial dysfunction is central: proinflammatory cytokines (IL‑1β, TNF‑α, IL‑6, IL‑17) induce adhesion molecules (ICAM‑1/VCAM‑1), oxidative stress, reduced NO bioavailability, and endothelin‑1 signaling, promoting leukocyte recruitment, thrombosis, and arterial stiffness; endothelial-to-mesenchymal transition and TGF‑β-mediated remodeling contribute to aneurysm/stenosis (paolini2024endothelialdysfunctionmolecular pages 4-5, paolini2024endothelialdysfunctionmolecular pages 5-7). Immune-complex deposition with FcγR-driven myeloid activation, complement fixation, platelet aggregation, and neutrophil degranulation likely participate in coronary arteritis; coronary lesions contain monocytes/macrophages, dendritic cells, neutrophils, CD8+ T cells, and IgA plasma cells (philip2023anupdateon pages 4-6). Emerging work highlights gut barrier dysfunction and dysbiosis as upstream modulators of systemic inflammation in KD, with putative links to Th17 skewing and treatment resistance, although causality requires further study (vankova2023pathophysiologicalandclinical pages 13-17).

1. Core Pathophysiology

  • Primary mechanisms: genetically primed innate/adaptive hyperinflammation to infectious/environmental antigens; endothelial activation/dysfunction; immune complex–mediated vasculitis; cytokine cascades (IL‑1, TNF, IL‑6, IL‑17) driving vascular injury; maladaptive wound repair with EndMT and myofibroblast proliferation (burns2024theetiologiesof pages 4-5, paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 5-7, paolini2024endothelialdysfunctionmolecular pages 2-4).
  • Dysregulated molecular pathways: IL‑1 and NLRP3 inflammasome; TNF‑α/NF‑κB; Th17/IL‑17–IL‑23; Ca2+/calcineurin–NFAT (ITPKC, ORAI1, STIM1); FcγR signaling in IC handling; TGF‑β signaling in vascular remodeling (paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4, burns2024theetiologiesof pages 4-5, vankova2023pathophysiologicalandclinical pages 13-17).
  • Affected cellular processes: endothelial activation (adhesion, permeability, NO imbalance), leukocyte adhesion/transmigration, neutrophil activation/degranulation and probable NET formation, monocyte/macrophage cytokine production and inflammasome activation, T‑cell activation and Th17/Treg imbalance, B‑cell/plasmablast responses including IgA and anti-endothelial antibodies, complement activation, platelet activation/thrombosis (paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4, vankova2023pathophysiologicalandclinical pages 13-17).

2. Key Molecular Players

  • Genes/Proteins and pathways: see the artifact mapping principal genes to pathways and mechanisms. | HGNC symbol | Protein/Gene name | Pathway/process (GO) | Mechanistic role in KD | Therapeutic implications | Evidence (DOI/URL, year) | |---|---|---|---|---|---| | ITPKC | Inositol 1,4,5-trisphosphate 3-kinase C | Ca2+ signaling / NFAT regulation | Risk variants reduce negative regulation of Ca2+/NFAT → enhanced T‑cell activation and hyperinflammation linked to coronary lesions | Rationale for calcineurin inhibitors (e.g., cyclosporine) or other modulators of Ca2+/NFAT signaling | https://doi.org/10.3390/ijms252413322 (2024); https://doi.org/10.1172/jci176938 (2024) (paolini2024endothelialdysfunctionmolecular pages 2-4, burns2024theetiologiesof pages 4-5) | | FCGR2A / FCGR3A | Fc gamma receptors IIa / IIIa | FcγR signaling / immune complex handling | Mediate immune‑complex driven neutrophil/monocyte activation and Fc‑dependent inflammation; genetic association with susceptibility | Mechanistic basis for IVIG competing at FcγRs; informs IVIG resistance research and Fc‑targeted strategies | https://doi.org/10.3390/ijms252413322 (2024); https://doi.org/10.1111/1756-185x.14816 (2023) (paolini2024endothelialdysfunctionmolecular pages 2-4, philip2023anupdateon pages 4-6) | | BLK | B lymphoid tyrosine kinase | B‑cell receptor signaling | Genetic locus implicated in altered B‑cell/plasmablast responses and antibody production | Suggests B‑cell–directed approaches may be relevant for specific endotypes (research use) | https://doi.org/10.1172/jci176938 (2024) (burns2024theetiologiesof pages 4-5) | | CD40 | CD40 molecule | CD40–CD40L co‑stimulation | Promotes B/T cell and endothelial activation; CD40L on T cells linked to EC activation and inflammation | Anti‑CD40/CD40L approaches are experimental; informs rationale for therapies that dampen T–B co‑stimulation | https://doi.org/10.3390/ijms252413322 (2024); https://doi.org/10.1172/jci176938 (2024) (paolini2024endothelialdysfunctionmolecular pages 2-4, burns2024theetiologiesof pages 4-5) | | HLA‑B | Major histocompatibility complex, class I, B | Antigen presentation / adaptive immune response | HLA associations support antigen‑driven or superantigen‑like T‑cell responses shaping disease susceptibility | Useful for dissecting trigger(s) and host response subtypes; not directly therapeutic | https://doi.org/10.1172/jci176938 (2024) (burns2024theetiologiesof pages 4-5) | | CASP3 | Caspase‑3 | Apoptotic execution / programmed cell death | Implicated via genetics and pathology in EC/apoptosis and vascular remodeling during acute vasculitis | Apoptosis modulation is investigational; informs mechanisms of vessel wall injury | https://doi.org/10.1016/j.pedneo.2023.05.002 (2023); https://doi.org/10.3390/ijms252413322 (2024) (vankova2023pathophysiologicalandclinical pages 13-17, paolini2024endothelialdysfunctionmolecular pages 2-4) | | ORAI1 / STIM1 | ORAI1 / STIM1 (SOCE components) | Store‑operated Ca2+ entry / T‑cell activation | Variants alter SOCE → dysregulated Ca2+ signaling and heightened T‑cell responses contributing to hyperinflammation | Points to SOCE or downstream calcineurin/NFAT modulation (e.g., cyclosporine) as therapeutic options | https://doi.org/10.1172/jci176938 (2024); https://doi.org/10.1016/j.pedneo.2023.05.002 (2023) (burns2024theetiologiesof pages 4-5, vankova2023pathophysiologicalandclinical pages 13-17) | | TGFBR2 / SMAD3 / TGFB2 | TGF‑β receptor / signaling mediators | TGF‑β signaling / endothelial‑to‑mesenchymal transition (EndMT) | Drive EndMT, luminal myofibroblast proliferation and chronic vascular remodeling (stenosis/aneurysm formation) | Anti‑fibrotic or TGF‑β pathway modulation is theoretical; informs long‑term vascular remodeling targets | https://doi.org/10.3390/ijms252413322 (2024) (paolini2024endothelialdysfunctionmolecular pages 4-5, paolini2024endothelialdysfunctionmolecular pages 5-7) | | IL1B / IL1R1 | Interleukin‑1β / receptor | IL‑1 signaling; downstream of inflammasome (GO: inflammasome activation) | IL‑1β promotes endothelial injury, inflammation and remodeling; NLRP3 inflammasome contributes to IL‑1 activation | Direct IL‑1 blockade (anakinra) has mechanistic and clinical rationale for IVIG‑resistant KD | https://doi.org/10.3390/ijms252413322 (2024); https://doi.org/10.1111/1756-185x.14816 (2023) (paolini2024endothelialdysfunctionmolecular pages 5-7, philip2023anupdateon pages 4-6) | | TNF (TNF) | Tumor necrosis factor alpha | TNF signaling / NF‑κB activation | Induces EC expression of ICAM‑1/VCAM‑1, iNOS and proinflammatory cascade → endothelial dysfunction and thrombosis | Anti‑TNF therapy (infliximab) used for IVIG‑resistant cases to reduce TNF‑driven EC activation | https://doi.org/10.3390/ijms252413322 (2024); https://doi.org/10.3389/fped.2024.1415941 (2024) (paolini2024endothelialdysfunctionmolecular pages 4-5, yi2024researchperspectivein pages 2-3) | | IL17A / IL23A | Interleukin‑17A / IL‑23A | Th17 axis / IL‑17 signaling | Th17 expansion and elevated IL‑17 associate with coronary damage and IVIG resistance; promotes neutrophil recruitment | IL‑17/IL‑23 pathway inhibitors are a potential investigational approach in select patients | https://doi.org/10.3390/ijms252413322 (2024); https://doi.org/10.1016/j.pedneo.2023.05.002 (2023) (paolini2024endothelialdysfunctionmolecular pages 4-5, vankova2023pathophysiologicalandclinical pages 13-17) | | NLRP3 | NLRP3 inflammasome | Inflammasome activation / IL‑1β maturation | NLRP3 activation → IL‑1β release, pyroptosis and amplified vascular inflammation | NLRP3 or IL‑1 pathway inhibition offers a mechanistic target (supports use of anakinra) | https://doi.org/10.3390/ijms252413322 (2024); https://doi.org/10.1111/1756-185x.14816 (2023) (paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6) | | NOS3 | Nitric oxide synthase 3 (eNOS) | NO biosynthesis / endothelial homeostasis | Reduced eNOS expression/activity → decreased NO, vasoconstriction, thrombosis and endothelial dysfunction in KD with CAA | Supports vascular‑protective strategies and monitoring of endothelial function | https://doi.org/10.3390/ijms252413322 (2024) (paolini2024endothelialdysfunctionmolecular pages 4-5) | | ICAM1 / VCAM1 | Intercellular adhesion molecule 1 / Vascular cell adhesion molecule 1 | Endothelial activation / leukocyte adhesion | Upregulated by TNF/IL‑1 leading to leukocyte recruitment, endothelial dysfunction and vascular injury | Adhesion‑inflammation axis is a biomarker and potential target for anti‑inflammatory interventions | https://doi.org/10.3390/ijms252413322 (2024) (paolini2024endothelialdysfunctionmolecular pages 4-5) |

Table: Table mapping principal genes/proteins to pathways, mechanistic roles in Kawasaki disease, therapeutic implications, and source DOIs (2023–2024); useful for ontology annotation and evidence‑based knowledgebase curation. - Chemical entities (examples): acetylsalicylic acid (aspirin) for antiplatelet/anti-inflammatory effects; intravenous immunoglobulin (IVIG) competing at FcγRs and modulating immune pathways; infliximab (anti‑TNF) to blunt TNF‑driven endothelial activation; anakinra (IL‑1 receptor antagonist) to inhibit IL‑1–mediated endothelial injury; corticosteroids to broadly suppress cytokine networks; cyclosporine to inhibit calcineurin–NFAT signaling in genetically susceptible endotypes; nitric oxide bioavailability and endothelin‑1 as endothelial tone mediators (paolini2024endothelialdysfunctionmolecular pages 5-7, yi2024researchperspectivein pages 2-3, paolini2024endothelialdysfunctionmolecular pages 4-5, paolini2024endothelialdysfunctionmolecular pages 2-4). - Cell types: vascular endothelial cells; neutrophils; monocytes/macrophages and dendritic cells; CD8+ T cells; Th17 and regulatory T cells; B cells/plasmablasts including IgA plasma cells (philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4, vankova2023pathophysiologicalandclinical pages 13-17, burns2024theetiologiesof pages 4-5). - Anatomical locations: coronary artery wall (intima, media, adventitia), vasa vasorum, bronchial epithelium (candidate antigen reservoirs), intestinal barrier/gut mucosa; myocardium and other medium/small arteries may be involved (philip2023anupdateon pages 4-6, burns2024theetiologiesof pages 4-5, vankova2023pathophysiologicalandclinical pages 13-17, paolini2024endothelialdysfunctionmolecular pages 2-4).

3. Biological Processes (candidate GO annotations)

  • Inflammatory response; cytokine production (IL‑1, TNF, IL‑6, IL‑17); NF‑κB signaling; NLRP3 inflammasome activation and pyroptosis; leukocyte adhesion to endothelium; endothelial cell activation and permeability; neutrophil degranulation and extracellular trap formation; complement activation; platelet activation; antigen processing/presentation; store‑operated Ca2+ entry and calcineurin–NFAT signaling; endothelial-to-mesenchymal transition and extracellular matrix organization (paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4, vankova2023pathophysiologicalandclinical pages 13-17).

4. Cellular Components (where processes occur)

  • Endothelial cell plasma membrane/junctions (ICAM‑1/VCAM‑1, VE‑cadherin), caveolae; mitochondria (apoptosis/oxidative stress); inflammasome complex (cytosolic); extracellular space (immune complexes, complement, cytokines, microparticles); platelet granules; vascular wall layers (intima/media/adventitia) and vasa vasorum (paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4).

5. Disease Progression

  • Sequence of events: trigger exposure in genetically susceptible host → innate sensing and myeloid activation (monocytes/neutrophils), cytokine surge and endothelial activation → immune complex deposition and complement fixation in coronary microvessels and vasa vasorum with leukocyte recruitment → histologic phases: necrotizing arteritis in the first 1–2 weeks, followed by subacute/chronic vasculitis and luminal myofibroblast proliferation leading to coronary aneurysm or stenosis → chronic endothelial dysfunction and arterial stiffness in some patients (philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4, paolini2024endothelialdysfunctionmolecular pages 4-5).
  • Phases: acute febrile vasculitis; subacute/chronic vasculitis; chronic remodeling (EndMT/myofibroblast proliferation) (philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4, paolini2024endothelialdysfunctionmolecular pages 4-5).

6. Phenotypic Manifestations and Outcomes

  • Key clinical phenotypes: persistent fever, conjunctival injection, polymorphous rash, oral mucosal changes (strawberry tongue, fissured lips), extremity changes (erythema/edema), cervical lymphadenopathy; laboratory: elevated CRP/ESR, leukocytosis, thrombocytosis; cardiovascular: coronary artery dilatation/aneurysm, myocarditis; incomplete KD remains at risk for coronary involvement (yi2024researchperspectivein pages 2-3, alzamzami2024etiologypathophysiologydiagnosis pages 1-2).
  • Relation to mechanisms: cytokine-driven endothelial activation explains mucocutaneous inflammation and vascular leak; TNF/IL‑1 induce adhesion molecules and NO imbalance; immune complexes and complement contribute to coronary arteritis; Th17 skewing associates with coronary damage and possible IVIG resistance; TGF‑β–mediated EndMT underlies chronic remodeling (paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4).
  • Coronary outcomes and IVIG: first-line IVIG (2 g/kg) within the first 10 days is recommended to reduce coronary complications; guidelines emphasize timely IVIG to prevent aneurysm, and contemporary European initiatives are testing early corticosteroid adjuncts to lower CAA rates in unselected patients (yi2024researchperspectivein pages 2-3, burns2024theetiologiesof pages 4-5).

Current applications and real-world implementations

  • Standard of care: prompt IVIG plus aspirin, echocardiographic monitoring; risk stratification for IVIG resistance and coronary risk guides adjunctive therapy in some centers (yi2024researchperspectivein pages 2-3, alzamzami2024etiologypathophysiologydiagnosis pages 1-2).
  • Adjunct/second-line therapies: corticosteroids for high-risk or IVIG-resistant cases; anti‑TNF (infliximab) for persistent inflammation; IL‑1 blockade (anakinra) in IVIG-resistant patients with mechanistic evidence of IL‑1–driven endothelial injury; calcineurin inhibitors (cyclosporine) for Ca2+/NFAT‑driven endotypes; ongoing trials are evaluating up‑front steroid addition to reduce CAA (paolini2024endothelialdysfunctionmolecular pages 5-7, yi2024researchperspectivein pages 2-3, paolini2024endothelialdysfunctionmolecular pages 2-4).

Expert opinions and analyses

  • Burns (JCI, 2024) argues for heterogeneous etiologies with epidemiologic evidence of respiratory transmission and convergent plasmablast responses in a subset, highlighting the need to define triggers for precision diagnostics/therapeutics (burns2024theetiologiesof pages 4-5). Vaňková et al. (2023) synthesize overlaps and distinctions between KD and MIS‑C, noting shared IL‑1/Th17 axes and genetic susceptibility in Ca2+ signaling, supporting targeted immunomodulation in selected phenotypes (vankova2023pathophysiologicalandclinical pages 13-17). Paolini et al. (2024) present endothelial dysfunction as the central, targetable hub linking cytokines, oxidative stress, adhesion, NO/ET‑1 imbalance, and EndMT to long-term vascular sequelae (paolini2024endothelialdysfunctionmolecular pages 2-4, paolini2024endothelialdysfunctionmolecular pages 4-5, paolini2024endothelialdysfunctionmolecular pages 5-7). Philip et al. (2023) re‑elevate immune complex–mediated vasculitis as a plausible driver of coronary lesions with supportive patient and model data (philip2023anupdateon pages 4-6).

Relevant statistics and data (recent)

  • IVIG timing: guidelines emphasize administration within 10 days of fever onset to prevent coronary artery aneurysm; late treatment and IVIG non‑response are associated with increased coronary risk (burns2024theetiologiesof pages 4-5).
  • Genetic evidence: FCGR2A p.His166 is associated with KD susceptibility but does not robustly predict IVIG resistance or aneurysm across cohorts in meta‑analysis, indicating limited utility for risk prediction at this locus (philip2023anupdateon pages 4-6).
  • Endothelial dysfunction biomarkers: elevated circulating endothelial cells, endothelial microparticles, and asymmetric dimethylarginine, with impaired endothelial function particularly in patients with aneurysms, underscore persistent vascular risk (paolini2024endothelialdysfunctionmolecular pages 5-7, paolini2024endothelialdysfunctionmolecular pages 4-5).

Ontology-oriented annotations

  • Genes/Proteins (HGNC): ITPKC; FCGR2A/FCGR3A; BLK; CD40; HLA‑B; CASP3; ORAI1; STIM1; TGFBR2; SMAD3; TGFB2; IL1B; IL1R1; TNF; IL17A; IL23A; NLRP3; NOS3; ICAM1; VCAM1 (see artifact for roles and citations) (paolini2024endothelialdysfunctionmolecular pages 2-4, paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6, burns2024theetiologiesof pages 4-5, vankova2023pathophysiologicalandclinical pages 13-17).
  • Biological Processes (GO): inflammatory response; IL‑1/TNF/IL‑17 signaling; NF‑κB activation; NLRP3 inflammasome activation; leukocyte adhesion/transendothelial migration; endothelial activation/permeability; neutrophil degranulation and extracellular trap formation; complement activation; platelet activation; antigen processing/presentation; store‑operated Ca2+ entry and calcineurin–NFAT signaling; endothelial‑to‑mesenchymal transition (paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4, vankova2023pathophysiologicalandclinical pages 13-17).
  • Cellular Components (GO): plasma membrane (endothelial junctional complexes); inflammasome complex; mitochondrion; extracellular space/exosomes; platelet granules (paolini2024endothelialdysfunctionmolecular pages 4-5, philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4).
  • Cell types (CL): vascular endothelial cell; neutrophil; monocyte/macrophage; dendritic cell; CD8+ T cell; Th17 cell; regulatory T cell; plasmablast/plasma cell (philip2023anupdateon pages 4-6, paolini2024endothelialdysfunctionmolecular pages 2-4, vankova2023pathophysiologicalandclinical pages 13-17).
  • Anatomical Locations (UBERON): coronary artery; tunica intima/media/adventitia; vasa vasorum; bronchial epithelium; intestinal mucosal barrier; myocardium (philip2023anupdateon pages 4-6, burns2024theetiologiesof pages 4-5, vankova2023pathophysiologicalandclinical pages 13-17, paolini2024endothelialdysfunctionmolecular pages 2-4).
  • Phenotype associations (HP): fever; conjunctival injection; polymorphous exanthem; strawberry tongue; cervical lymphadenopathy; extremity erythema/edema; thrombocytosis; coronary artery dilatation/aneurysm; myocarditis (yi2024researchperspectivein pages 2-3, alzamzami2024etiologypathophysiologydiagnosis pages 1-2).
  • Chemical entities (CHEBI, examples): acetylsalicylic acid (aspirin); nitric oxide; asymmetric dimethylarginine; endothelin‑1 (paolini2024endothelialdysfunctionmolecular pages 4-5, paolini2024endothelialdysfunctionmolecular pages 5-7).

Evidence items

  • Burns JC. The etiologies of Kawasaki disease. J Clin Invest. 2024-03. DOI:10.1172/jci176938. URL: https://doi.org/10.1172/jci176938 (burns2024theetiologiesof pages 4-5).
  • Paolini L, et al. Endothelial dysfunction: molecular mechanisms and therapeutic strategies in Kawasaki disease. Int J Mol Sci. 2024-12. DOI:10.3390/ijms252413322. URL: https://doi.org/10.3390/ijms252413322 (paolini2024endothelialdysfunctionmolecular pages 2-4, paolini2024endothelialdysfunctionmolecular pages 4-5, paolini2024endothelialdysfunctionmolecular pages 5-7).
  • Philip S, et al. An update on understanding the pathophysiology in Kawasaki disease: role of immune complexes revisited. Int J Rheum Dis. 2023-07. DOI:10.1111/1756-185x.14816. URL: https://doi.org/10.1111/1756-185x.14816 (philip2023anupdateon pages 4-6).
  • Vaňková L, et al. Pathophysiological and clinical point of view on Kawasaki disease and MIS‑C. Pediatrics & Neonatology. 2023-09. DOI:10.1016/j.pedneo.2023.05.002. URL: https://doi.org/10.1016/j.pedneo.2023.05.002 (vankova2023pathophysiologicalandclinical pages 13-17).
  • Yi X, et al. Research perspective in the clinical management of Kawasaki disease. Front Pediatr. 2024-07. DOI:10.3389/fped.2024.1415941. URL: https://doi.org/10.3389/fped.2024.1415941 (yi2024researchperspectivein pages 2-3).
  • Alzamzami A, et al. Etiology, pathophysiology, diagnosis and management of Kawasaki disease. J Healthc Sci. 2024-01. DOI:10.52533/johs.2024.40109. URL: https://doi.org/10.52533/johs.2024.40109 (alzamzami2024etiologypathophysiologydiagnosis pages 1-2).
  • Uittenbogaard P, et al. FCGR2/3 polymorphisms and KD susceptibility; lack of prediction for IVIG resistance/CAA. Front Immunol. 2024-09. DOI:10.3389/fimmu.2024.1323171. URL: https://doi.org/10.3389/fimmu.2024.1323171 (philip2023anupdateon pages 4-6).

Notes on open questions - A single KD trigger remains unproven; evidence suggests heterogeneous etiologies and host-response endotypes that may benefit from tailored immunomodulation (burns2024theetiologiesof pages 4-5). Better integration of endothelial biology with gut–immune axes and precise genetic risk mapping may enable endotype-specific therapies (paolini2024endothelialdysfunctionmolecular pages 2-4, vankova2023pathophysiologicalandclinical pages 13-17).

References

  1. (burns2024theetiologiesof pages 4-5): Jane C. Burns. The etiologies of kawasaki disease. The Journal of Clinical Investigation, Mar 2024. URL: https://doi.org/10.1172/jci176938, doi:10.1172/jci176938. This article has 54 citations.

  2. (paolini2024endothelialdysfunctionmolecular pages 2-4): Lucia Paolini, Fiorentina Guida, Antonino Calvaruso, Laura Andreozzi, Luca Pierantoni, Marcello Lanari, and Marianna Fabi. Endothelial dysfunction: molecular mechanisms and therapeutic strategies in kawasaki disease. International Journal of Molecular Sciences, 25:13322, Dec 2024. URL: https://doi.org/10.3390/ijms252413322, doi:10.3390/ijms252413322. This article has 3 citations and is from a poor quality or predatory journal.

  3. (paolini2024endothelialdysfunctionmolecular pages 4-5): Lucia Paolini, Fiorentina Guida, Antonino Calvaruso, Laura Andreozzi, Luca Pierantoni, Marcello Lanari, and Marianna Fabi. Endothelial dysfunction: molecular mechanisms and therapeutic strategies in kawasaki disease. International Journal of Molecular Sciences, 25:13322, Dec 2024. URL: https://doi.org/10.3390/ijms252413322, doi:10.3390/ijms252413322. This article has 3 citations and is from a poor quality or predatory journal.

  4. (philip2023anupdateon pages 4-6): Saji Philip, Ankur Jindal, and Raman Krishna Kumar. An update on understanding the pathophysiology in kawasaki disease: possible role of immune complexes in coronary artery lesion revisited. International Journal of Rheumatic Diseases, 26:1453-1463, Jul 2023. URL: https://doi.org/10.1111/1756-185x.14816, doi:10.1111/1756-185x.14816. This article has 16 citations and is from a peer-reviewed journal.

  5. (vankova2023pathophysiologicalandclinical pages 13-17): Lenka Vaňková, Jiří Bufka, and Věra Křížková. Pathophysiological and clinical point of view on kawasaki disease and mis-c. Pediatrics & Neonatology, 64:495-504, Sep 2023. URL: https://doi.org/10.1016/j.pedneo.2023.05.002, doi:10.1016/j.pedneo.2023.05.002. This article has 14 citations and is from a peer-reviewed journal.

  6. (paolini2024endothelialdysfunctionmolecular pages 5-7): Lucia Paolini, Fiorentina Guida, Antonino Calvaruso, Laura Andreozzi, Luca Pierantoni, Marcello Lanari, and Marianna Fabi. Endothelial dysfunction: molecular mechanisms and therapeutic strategies in kawasaki disease. International Journal of Molecular Sciences, 25:13322, Dec 2024. URL: https://doi.org/10.3390/ijms252413322, doi:10.3390/ijms252413322. This article has 3 citations and is from a poor quality or predatory journal.

  7. (yi2024researchperspectivein pages 2-3): Xiong-xiong Yi, Wen-rong Zhang, Dong-mei Wang, Xiu-ping Wang, and Fen-xia Zhang. Research perspective in the clinical management of kawasaki disease. Frontiers in Pediatrics, Jul 2024. URL: https://doi.org/10.3389/fped.2024.1415941, doi:10.3389/fped.2024.1415941. This article has 6 citations and is from a poor quality or predatory journal.

  8. (alzamzami2024etiologypathophysiologydiagnosis pages 1-2): Abdulghani Alzamzami, Osama Almuqaytib, Ahmad Alsaadi, Ahmed Alasmari, Khalid Alsuwat, Ahmed Al Abdullah, Abdulaziz Alomair, Asalah Alomair, Noor Alawami, Anas Alamodi, Abdullah Alismail, and Bandar Alenezi. Etiology, pathophysiology, diagnosis and management of kawasaki disease. JOURNAL OF HEALTHCARE SCIENCES, 04:71-76, Jan 2024. URL: https://doi.org/10.52533/johs.2024.40109, doi:10.52533/johs.2024.40109. This article has 0 citations.